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ABSTRACT 
 
Tumor heterogeneity observed between patients has made it challenging 
to develop universal or broadly effective cancer therapies. Therefore, an ever-
growing movement within cancer research aims to tailor cancer therapies to 
individual patients or specific tumor subtypes. Tumor stratification is generally 
dictated by the genomic mutation status of the tumor cells themselves. 
Importantly, non-genetic influences – such as interactions between tumor cells 
and other components of the tumor microenvironment – have largely been 
ignored. Therefore, in an effort to increase treatment predictability and efficacy, 
we investigated how tumor-stroma interactions contribute to drug sensitivity and 
drug resistance. 
I designed a high throughput co-culture screening platform to measure 
how tumor-stroma interactions alter drug mediated cell death. I identified tumor-
stroma interactions that strongly desensitize or sensitize cancer cells to various 
drug treatments. The directionality of these observed phenotypes was dependent 
on the stromal cell tissue of origin. Further study revealed that interactions 
between tumor cells and fibroblasts modulate apoptotic priming in tumor cells to 
mediate sensitivity to chemotherapeutics. The principles uncovered in this study 
have important implications on the use of drugs that are designed to enhance 
apoptosis. For example, based on our screening data, I hypothesized and 
experimentally validated that the effectiveness of BH3 mimetic compounds would 
be strongly dependent on the fibroblast growth environment. Taken together, our 
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study highlights the importance of understanding how environmental interactions 
alter the drug responses of cancer cells and reveals a mechanism by which 
stromal cells drive broad spectrum changes in tumor cell sensitivities to common 
chemotherapeutics.  
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CHAPTER I: INTRODUCTION 
 
 Cancer is one of the leading ailments worldwide, accounting for roughly 1 
in 7 deaths according to recent data from the American Cancer Society. 
Throughout the 20th and 21st century, great strides have been made both in our 
understanding of the underlying biology of cancer cells, and in the development 
of therapies to treat a range of tumor types. However, cancer is a heterogeneous 
disease, in which patient-to-patient variability prevents the creation of a single 
universal cure. Therefore, it is likely necessary to tailor therapies to the features 
of an individual cancer type, or even an individual patient tumor. Yet, an 
important unanswered question remains: what information should be considered 
for optimal disease stratification? My thesis research is focused on 
understanding the contribution of the tumor microenvironment to treatment 
outcomes. Currently, disease stratification is dominated by the identification of 
specific genomic mutations or aberrations, with little regard for environmental 
contributions. In contrast, I aimed to test how different normal cells that reside 
within tumors influence cancer cell drug sensitivity. This information may 
ultimately be valuable for predicting optimal therapies and improving patient 
survival rates.  
In the remainder of my thesis introduction, I will explore the history of 
chemotherapy, from the advent and use of traditional cytotoxic agents, to more 
modern targeted therapies. A key argument will be that our pursuit of novel 
therapeutic targets needs to evolve beyond genomic identification of “oncogenic 
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drivers”, and should also include cell non-autonomous sources, such as the 
tumor microenvironment. I have developed a high-throughput assay optimized to 
measure cell death to test the effect of environmental perturbations on cancer 
drug sensitivity, using triple-negative breast cancer (TNBC) as a model system, 
and fibroblasts derived from different anatomical locations as an environmental 
variable. A statistical and bioinformatic analysis of this study revealed an 
understanding of the interactions that control tumor drug response, and I 
investigated the molecular mechanisms responsible for fibroblast dependent 
changes in TNBC drug sensitivity. The insight gained from my data will advance 
the field’s understanding how cell death is regulated in the context of cancer 
treatment and may result in an improved ability to create more effective drug 
combinations for treating aggressive tumors. 
 
Traditional Methods of Cancer Treatment 
Surgery 
The earliest treatment of cancer was the use of surgical excision, dating 
back to ancient times, with records detailing Roman physicians removing the 
breast tissue of women with malignant tumors1. Although physicians would 
excise the tumorous tissue, they would later observe the recurrence of cancerous 
tumors in patients, with the Roman physician Celsus noting “After excision, even 
when a scar has formed, none the less the disease has returned”2. As a result, 
Roman physician Galen promoted the idea of rarely performing surgery as it 
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often accelerated death due to surgical complications rather than cure the 
disease1,3,4. 
Advances in aseptic techniques reduced the number of complications from 
surgery allowing physicians to remove more and more tissue around the tumor 
mass. These advances culminated in a procedure called Halsted’s radical 
mastectomy4. This procedure initially included only removal of the entire breast 
tissue, but then advanced to include removal of the regional lymphatics, and 
eventually also included removal of the pectoralis muscles. However, a key issue 
that was not addressed by even the most aggressive surgical methods was the 
existence of distant growths of tumor cells, called metastases.  
By the late 1950’s, Bernard and Edwin Fisher began to investigate the 
biology of tumor metastasis and would eventually invalidate Halsted’s use of 
radical surgery as the ideal cancer treatment. Fisher proposed that cancer was 
both a regional and systemic disease and that primary tumors had the ability to 
yield cancer cells that could disseminate throughout the body using the lymphatic 
and circulatory systems4. To test this contradicting hypothesis, Fisher conducted 
a series of experiments that included tracking radiolabeled cancer cells traveling 
through the blood stream, as well as measuring the impact of removing regional 
lymph nodes on the occurrence of metastases5–7. Based on these data, Fisher 
concluded that radical surgeries to remove large amounts of tissue could not 
prevent tumor metastasis, which prompted a clinical trial to compare Halsted’s 
mastectomy to less invasive procedures. Surprisingly, this study found no 
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significant difference between the treatment groups in 25 years of follow up 
appointments8. These findings shifted the standard surgical treatment of cancer 
to less invasive surgeries. 
Although there have been great advances in the field of cancer surgery, 
surgical removal of the tumor by itself is generally not sufficient to cure cancer 
due to tumor cells leaving the primary site4. Cancer metastasis has spurred the 
search for finding new treatment strategies to pair with cancer surgery that can 
target cells that were left behind after surgical excision.  
 
Radiation Therapy 
Despite surgery being the main technique to treat cancers in the late 19th 
century and early 20th century, some cancer types, such as head and neck 
cancers, were inoperable leading to the critical need for alternative treatment 
methods. The field of radiation oncology began after the discoveries of X-rays by 
Wilhelm Roentgen in 1895 and the discovery of radium by Marie and Pierre 
Curie9,10. Early treatments consisted of giving patients a single large dose of 
radiation which would kill the tumor but at the cost of heavy damage to the 
surrounding normal tissue, which prompted the development of frequent smaller 
doses – called fractionated radiotherapy – to minimize harm to surrounding 
normal tissue9,11,12. During the same time period it was shown that radiation 
exposure induced mutations in DNA and that rapidly dividing cells and 
undifferentiated cells, such as the gametes, were more susceptible to radiation 
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treatments13–15. This prompted the study of how DNA damage could be used to 
preferentially kill cancer cells. However, this topic is still a matter of great debate, 
and a consensus has not been reached regarding the reasons why DNA damage 
preferentially kills tumor cells. Currently roughly 50% of patients receive radiation 
therapy as part of the treatment of cancer, whether alone or in conjunction with 
surgery16. Yet, radiation therapy remains a local cancer therapy and the need to 
treat metastatic tumors has led to the development of more systemic treatment 
options.  
 
Cytotoxic Chemotherapies 
The need for a systemic treatment to eradicate both the primary tumor 
tissue and metastatic cells cultivated the use of chemical compounds as a 
treatment method. One of the first chemical compounds used as a cancer 
therapeutic was the use of nitrogen mustard in treating non-Hodgkin’s lymphoma. 
Alfred Gilman and Louis Goodman showed that nitrogen mustard gas could be 
used to reduce tumor burden a rodent model of lymphoid tumors and Gustaf 
Lindskog showed the efficacy in lymphomas in human patients17–19.  
Nitrogen mustards induce DNA damage in cancer cells by forming bulky 
DNA adducts as well as intra or inter-strand crosslinks20. Crosslinks on DNA lead 
to the disruption of the transcription machinery and, during DNA replication, 
double strand breaks as well as replication lesions21. The observation that DNA 
damage induced by nitrogen mustards kills cancer cells, while minimizing 
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damage to the surrounding normal tissue, led to the creation of a wide variety of  
DNA damaging chemotherapeutics which can be summarized in table 1.1. 
 
Damage to DNA activates a signaling pathway called the DNA Damage 
Response (DDR), which coordinates several cell behaviors, including cell growth 
arrests, DNA repair, and, if the damage is severe, activation of programmed cell 
death22. There are three layers to the DDR, proteins that sense DNA damage, 
proteins that transmit and amplify the signal, and effector proteins that coordinate 
the cellular processes of cell cycle arrest, repair or death (see Figure 1.1 for 
overview). For single strand breaks (SSBs), RPA coated DNA recruits and  
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activates the ataxia telangiectasia RAD3-related (ATR) kinase. ATR in turn 
phosphorylates and activates the checkpoint kinase CHK1, which phosphorylates 
many targets, including CDC25 causing cell cycle arrest23. In the case of double 
strand breaks (DSBs), the MRE11-RAD50-NDS1 (MRN) complex is recruited to 
the damage site and recruits the ataxia telangiectasia mutated (ATM) kinase. 
ATM is activated by autophosphorylation and propagates the damage signal by 
phosphorylating and activating the checkpoint kinase CHK2. This kinase then 
phosphorylates and activates effector proteins such as CDC25A, resulting in cell 
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cycle arrest, BRCA1, resulting in activation of repair machinery to fix the DSBs as 
well as S-phase arrest, and p53, resulting in cell cycle arrest or induction of 
apoptosis24.  
Chemical compounds that induce DNA damage are thought to leverage 
inherent differences in DNA damage sensitivity between cancerous and non-
cancerous cells. In some cases, the sources of this difference are well 
understood. For example, some cancer cells have compromised DNA repair 
machinery. In most cases however, the sources of these differences are not 
clear. A common interpretation is that DNA damage targets all rapidly dividing 
cells. This speculation was recently tested by Tony Letai and colleagues who 
found it to be a poor explanation of their data, as they observed that many slow 
growing cancers are sensitive to DNA damage and many fast growing tissues 
are insensitive25. They later demonstrated that chemosensitivity was more 
closely correlated to the intrinsic apoptotic priming state of the cancer cells.  
In addition to chemical compounds that cause direct DNA damage, many 
effective compounds function by interfering with cell cycle progression and cell 
division. During studies concerning nutrient requirements for proper 
development, it was observed that folic acid deficiencies in humans led to 
reduced bone marrow, similar to effects of mustard gas exposure. This 
observation spurred Sydney Farber to develop a series of folate antagonists, 
such as methotrexate, for the treatment of children with leukemia26. Methotrexate 
binds to dihydrofolate reductase (DHFR), outcompeting folate, and prevents the 
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formation of tetrahydrofolate, an important co-factor in the synthesis of 
thymidine26. The resulting decrease in nucleotide pools activates the G1/S cell 
cycle checkpoint and arrests proliferation27. However, cells that are progressing 
through S-phase or cancers that are checkpoint deficient incur DNA damage due 
to deficient nucleotide pools which results in cell death27,28. Recently, it has been 
also been shown that 5-FU and FUDR, chemotherapeutics that also affect 
thymidine synthesis, induce cell death through bacterial ribonucleotide 
metabolism in an in vivo environment using C. elegans as a model organism29. 
The G1/S checkpoint and entry into the cell cycle was not the only targetable cell 
cycle phase as drugs were developed to disrupt cell progression through mitosis 
and division.  
During the 1960s the National Cancer Institute set up a chemical 
screening platform to test the efficacy of compounds submitted by scientists and 
companies. One such screen tested extracts of over 1,000 plant species and 
observed that a compound in bark from the Taxus brevifolia tree was toxic to 
cancer cells30. This compound, later named paclitaxel, was found to target the 
protein tubulin and stabilize microtubules from disassembling31,32. Stabilization of 
microtubules results in the inability to properly form of the mitotic spindle causing 
cell cycle arrest during mitosis. Checkpoint deficient cells that progress through 
mitosis incur DNA damage through improper segregation of the chromosomes, 
resulting in cell death, while cells that experience prolonged activation of the 
mitotic checkpoint activate apoptosis, also resulting in cell death33. The 
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development of the aforementioned compounds, which act on pathways that are 
intrinsic to all cells and are able to circulate throughout the body, allowed for the 
treatment cancer in a systemic manner. These compounds, along with surgery 
and radiotherapy, have greatly improved outcomes for many cancer patients. 
Unfortunately, for many subtypes of cancer – and for essentially all types of 
metastatic cancer – effective therapies are still lacking, underscoring the need for 
new therapeutic concepts. 
 
Mechanisms of Cell Death 
Apoptosis 
 The ability of a cell to commit death, when needed, is a necessary and 
highly regulated process. One of the most common forms of programmed cell 
death is apoptosis, a non-inflammatory process that kills cells using 
mitochondrial rupture and caspase activation. Apoptosis is controlled by two 
pathways, the intrinsic apoptotic pathway, which responds to internal cellular 
stresses like DNA damage, and the extrinsic apoptotic pathway, which responds 
to extracellular signals, such as TNF34–37.   
In brief, the intrinsic apoptotic pathway is initiated by stress signals, which 
lead to the formation of pores in the mitochondrial outer membrane. A critical 
event following mitochondrial outer membrane permeabilization (MOMP) is 
release of cytochrome C, which catalyzes formation of the apoptosome. The 
critical function of the apoptosome is cleavage and activation of “executioner” 
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caspases, such as caspase-3. Historically, activation of executioner caspases 
was considered the mechanism of cell death (active caspases are proteases that  
 
can cleave a wide variety of protein substrates, leading to cell death); however, it 
is now generally accepted that cells cannot survive following MOMP. Thus, 
downstream activation of effector caspases is more likely involved in suppressing 
the release of inflammatory signals from apoptotic corpses. The extrinsic 
apoptotic pathway is initiated by the binding of cognate signaling molecules to a 
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class of cell surface proteins called death receptors. Ligand binding leads to 
oligomerization, recruitment of adaptor proteins, and ultimately to the recruitment 
and activation of the initiator caspases 8/10. These initiator caspases in turn 
activate the effector caspases to induce protein cleavage as well as cleave the 
protein BID to facilitate Mitochondrial Outer Membrane Permeabilization (MOMP) 
and release of cytochrome C (See Figure 1.2 for an overview).  
In the context of drug therapy, the degree of cell death is a function of two 
properties: the degree to which the drug activates the intrinsic or extrinsic 
pathways, and the degree to which the cell is “primed” for death. Apoptotic 
priming is thought to be controlled by the local ratio of pro- and anti-apoptotic 
proteins at the mitochondrial membrane (see figure 1.3 for an overview). When 
pro-apoptotic signals outweigh the anti-apoptotic signals, the cell passes the 
apoptotic threshold and is committed to cell death36. Identification and 
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measurement of the apoptotic threshold has been challenging as it is a function 
of protein expression, location, and a complex network of interactions. Recently 
an assay has been developed, called BH3 profiling, that determines the apoptotic 
threshold of cells by measuring the amount of synthetic pro-apoptotic peptide 
required to rupture a cells mitochondria38.  
Modulation of apoptosis can occur either by altering the drug induced 
signaling dynamics or by altering the levels of pro or anti-apoptotic proteins. It 
has been shown that interaction with the microenvironment, in this instance 
cancer associated fibroblasts, is able to change cancer cell drug response 
through mediating apoptotic priming39. However, it is unclear if alternate signals 
from the tumor microenvironment change how damage signaling is processed to 
alter the onset of apoptosis.  
 
Breast Cancer 
Breast cancer is the most frequently diagnosed cancer among American 
and European women40,41. Despite improvements in therapy that have increased 
survival rates, breast cancer remains the second leading cause of cancer deaths 
in women worldwide42. Breast cancer is a heterogeneous disease comprising of 
several subtypes with distinct histological, molecular, and clinical features. Triple 
negative breast cancer (TNBC) is a subtype of breast cancer that accounts for 
nearly 20% of patient cases42. TNBC is characterized by the absence of the 
amplification of the estrogen receptors, progesterone receptors, and excess 
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HER2 protein. Due to the lack of targetable receptors, TNBCs have limited 
therapeutic options and are commonly treated with DNA damaging agents.  
Breast cancers cause death by metastasizing to secondary organs and 
interfering with essential biological functions. TNBC is one of the most 
aggressive subtypes of breast cancer and metastasizes mainly to the brain, 
lungs, liver or bone marrow. Once TNBCs have metastasized to a secondary site 
they become less sensitive to chemotherapeutics that were effective at treating 
the primary tumor. This fact has spurred the need for a better understanding on 
what factors contribute to drug resistance at secondary sites. In this thesis I aim 
to explore how microenvironmental factors, primarily fibroblasts, contribute to this 
change in drug sensitivity.  
When designing my screening platform, I took care to choose fibroblasts 
from common metastatic sites of TNBC as well as non-common metastatic sites. 
This decision was made not only to increase the diversity of the fibroblast panel 
but to explore whether the microenvironment of metastatic sites differentially 
altered the sensitivity of TNBC. I hypothesized that fibroblasts derived from 
common metastatic sites would desensitize TNBC cell lines to DNA damaging 
agents while fibroblasts from non-metastatic sites would have no effect on drug 
sensitivity. 
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Tumor Microenvironment 
 It is becoming well appreciated that tumor-stroma interactions can alter 
many behaviors of tumor cells, including growth rate, gene expression state, and 
even drug responses. Therefore, to effectively treat cancer, it is crucial to 
understand the nature of tumor-stroma interactions, and in particular, which 
interactions cause changes in drug sensitivity. Most studies that investigate the 
tumor microenvironment use in vivo systems. While these studies demonstrate 
the importance of the tumor microenvironment for various tumor phenotypes, 
they are generally unable to dissect which specific interactions contribute to the 
phenotype due to the complexity of the tumor microenvironment. In my thesis, I 
aim to use an in vitro co-culture system, in which I can selectively vary one 
component of the microenvironment, to investigate the role of individual 
environmental components on cancer cell drug sensitivity and cell death. For my 
initial study I chose to investigate the role of cancer associated fibroblast on 
cancer cell drug sensitivity and cell death.  
 
CAFS 
 Normal fibroblasts maintain normal tissue structure and function through 
the deposition of matrix and secretion of both cytokines and growth factors. 
During tumorigenesis, cancer cells hijack normal fibroblasts whose gene 
expression pattern changes to promote tumor, growth, angiogenesis, invasion 
and metastasis. Cancer associated fibroblasts (CAFs) adopt a gene expression 
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state similar to myofibroblasts, a cell type rarely observed in healthy tissue but 
involved in wound healing43. CAFs are identified by the expression of distinct 
marker proteins such as α smooth muscle actin (α SMA), fibroblast activation 
protein (FAP), and fibroblast specific protein 1 (FSP1)43. Resident normal 
fibroblasts primarily differentiate into CAFs by responding to signals from cancer 
cells, such as TGF-b, miR-31, miR-214, miR155, and CXCL12, but other cell 
types have also been observed to adopt a CAF like gene expression state44,45.  
CAFs in the tumor microenvironment secrete a wide range of signaling 
molecules that support cancer cells during tumorigenesis. CAFs promote cell 
proliferation by secreting growth factors such as the hepatocyte growth factor 
(HGF), fibroblast growth factor (FGFs) and insulin-like growth factor 1 (IGF1)46–48. 
Invasion and metastasis are promoted by the secretion of metalloproteases that 
degrade the surrounding extracellular matrix as well as TGF-b that aids in the 
EMT transitions of metastatic cancer cells43,46. CAFs not only create an 
environment for cancer cells to thrive but they are able to modulate cancer cells’ 
response to chemotherapeutic drugs. Studies have shown that CAFs desensitize 
cancer cells to targeted agents, however there is a dearth of knowledge in how 
interactions with fibroblasts mediate DNA damage induced death39,49. My thesis 
research will focus on studying the interactions between fibroblasts and triple-
negative breast cancer cells and identifying tumor-stroma co-culture conditions 
that alter cancer cell drug sensitivity. I will explore the extent of the role these 
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interactions have in modulating apoptotic signaling dynamics as wells as the 
apoptotic threshold.  
There have been few studies that have investigated the effect of the tumor 
microenvironment on cancer drug sensitivity, specifically with a focus on 
fibroblasts. Straussman et al. was one of the first studies that explored these 
complex interactions between tumor cells and fibroblasts. In this study, the 
authors developed a high throughput co-culture system to screen the interactions 
between 23 fibroblasts and 45 cancer cells when treated with 35 
chemotherapeutics. The study demonstrated that fibroblast mediated 
desensitization to chemotherapeutics is common, especially to targeted agents, 
and further identified an interaction where fibroblast secretion of HGF decreased 
the effeteness of RAF inhibition in BRAF-mutant melanoma49. Marusyk et al. 
further advanced the field with their study showing that CAFs derived from breast 
tissue or brain metastases increased the resistance of HER2+ breast cancer 
cells to the targeted inhibitor lapatinib39. The study also demonstrated that normal 
fibroblasts derived from breast or brain tissue had the same effect on cancer cell 
drug response as CAFs.  
 Despite the previous studies laying a strong foundation, there are gaps in 
the data that I aim to address in this thesis. First, both studies focused on 
targeted cancer therapies and did not determine how fibroblasts effect of DNA 
damaging agents in a comprehensive manner. Second, neither study had a focus 
on TNBC, with the Straussman et al. study spanning seven different cancer types 
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and the Marusyk et al. study focusing on HER2+ breast cancer. Futhermore, 
neither study investigated whether there was a difference in fibroblast mediated 
changes in chemosensitvity based on whether the fibroblast was derived from a 
common metastatic or non-common metastatic site for that cancer type. Marusyk 
et al. focused on CAFs derived from either the primary breast tissue or 
metasteses from the brain, a common metastatic environment for breast cancer. 
The diversity of the cancer types in the Staussman et al. study prevented them 
from investigaing the division between metastaitic and non-metastatic fibroblasts, 
with the study mainly spanning three different fibrobalst types focusing on skin, 
lung, and breast. In this thesis, I aim to screen TNBCs treated with a 
comprehensive list of chemotherapeutics co-cultured with either fibroblasts 
derived from common or non-common metastatic sites using an assay that 
specifically measure cell death. I aim to address some of the gaps in the 
literature presented above and advance the knowledge of the field in order to 
create more effective therapies for the treatment of TNBC.  
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CHAPTER II: A GFP-based co-culture methodology identifies fibroblast 
mediated desensitization of cancer cells to erlotinib and but fails to 
measure cell death. 
 
Abstract: 
 The tumor microenvironment plays a pivotal role in the growth, 
progression, and survival of cancer cells. Cancer associated fibroblasts (CAFs) 
are one of the main components of the tumor microenvironment and have 
recently been shown to alter cancer cell drug sensitivity to targeted agents. Yet, it 
remains unclear how these interactions mediate cancer cell drug sensitivity to 
cytotoxic agents. Identification of novel fibroblast-tumor interactions that 
modulate drug sensitivity, as well as understanding the underlying molecular 
mechanisms, will aid in the development of more effective strategies to treat 
cancer patients. However, identifying these interactions is challenging due to the 
need to capture robust cell viability measurements, specific to the cancer cell 
population, in co-culture. Here, I demonstrate that a GFP-based co-culture assay 
captures fibroblast mediated cancer cell proliferation effects but fails to 
accurately measure cancer cell death. Additionally, co-culture induces a pro-
growth effect in cancer cells and reduces the effectiveness of the targeted 
inhibitor erlotinib. The magnitude of these phenotypes is dependent on the 
fibroblast:cancer ratio, with the magnitude increasing as the ratio increases, as 
well as the tissue identity that the fibroblast was obtained from. This study 
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highlights the need to develop a new assay, optimized in measuring cancer cell 
specific death in co-culture, to investigate the effect of fibroblast-cancer 
interactions on cancer cell drug sensitivity to cytotoxic agents.  
 
Introduction: 
Drug resistance remains a challenging hurdle to overcome in the 
treatment of cancer patients. Complete tumor remission following exposure to 
either cytotoxic or targeted agents is rare, and a growing body of evidence 
suggests that environmental interactions play a role in mediating cancer drug 
resistance50. One of the most abundant non-malignant cell types that reside 
within tumors are cancer associated fibroblasts (CAFs). These normal stromal 
cells play an active role in remodeling the tumor microenvironment to promote 
tumor growth and progression43,51–53. CAFs are a major source of growth factors, 
cytokines, and matrix deposition. Each of these factors has been shown to alter 
cancer cell sensitivity to targeted therapies39,49. However, there remains a lack of 
understanding of how CAF mediated interactions with tumor cells modulate drug 
response to cytotoxic agents.  
A mechanistic understanding of how interactions between fibroblasts and 
cancer cells modulate the behaviors of tumors has been a challenge due to 
heterogeneity within and between patients/animals. Primary tumors can 
metastasize to a variety of locations in the body and interact with tissue specific 
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fibroblasts. Therefore, characterization of these interactions requires the study of 
fibroblasts obtained from a variety of anatomical locations. 
A successful assay to measure the effect of fibroblasts on cancer cell drug 
response contains the ability to measure the viability of the cancer cell population 
independent of the fibroblast cells. A high-throughput co-culture assay has been 
developed, which uses GFP-labeled cancer cells and unlabeled fibroblasts. 
Measuring GFP fluorescence is used to specifically quantify the life/death of 
cancer cells regardless of the existence of other non-cancer cell types. 
Furthermore, GFP is amenable to measurement using a fluorescent plate reader, 
facilitating high-throughput and time-resolved measurements. This technique was 
recently used to test a large number of fibroblast-cancer-drug interactions and 
revealed a mechanism for fibroblast mediated resistance to targeted RAF-
inhibitors49. In this chapter, I demonstrate that the GFP based screening assay is 
proficient in capturing fibroblast-cancer-drug interactions that effect cell 
proliferation but is not accurate in measuring cell death. I show that fibroblasts 
generally induce a pro-proliferative phenotype when co-cultured with lung and 
breast cancer cell lines, as well as describe a tissue specific drug desensitization 
interaction in the lung cancer line A549 when treated with the EGFR inhibitor 
erlotinib. When testing the assay with cytotoxic agents, I found that the use of 
GFP-labeled cells was not accurate in measuring cell death. 
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Results: 
To test the ability of a recently published in vitro GFP-based assay to 
measure tumor-fibroblast mediated effects on drug sensitivity, I piloted a small 
screen designed to measure assay sensitivity in capturing proliferation and cell 
death phenotypes. I selected a panel of primary fibroblasts to be co-cultured, at 
varied ratios, with either triple-negative breast cancer (TNBC) or lung cancer cell 
lines that were stably transfected to constitutively express a soluble cytoplasmic 
GFP molecule. Each co-culture condition was treated with the targeted agent 
erlotinib, an EGFR inhibitor, or the cytotoxic drug camptothecin, a topoisomerase 
inhibitor (Fig. 2.1A). Included in the panel was a TNBC cell line, BT20, whose 
interactions with both erlotinib and camptothecin in mono-culture have previously 
been described54. To determine the basal effect of co-culture on the growth rate 
of tumor cells in the absence of any drug, I compared the growth rates of cancer 
cells grown in mono-culture or in co-culture with fibroblasts. Relative growth rate 
was approximated using the area under the curve (AUC) of the growth time 
course (Fig 2.1B). Generally, co-culture of tumor cells with fibroblasts promoted 
increased cancer cell growth, regardless of fibroblast tissue identity. This growth 
phenotype scaled with the fibroblast:cancer ratio, with a greater proliferative 
advantage seen as the fibroblast:cancer ratio is increased (Fig 2.1B and D). 
Surprisingly, I observed a growth disadvantage in the TNBC line MDA-MB-231 
when cultured with fibroblasts derived from the tissue of origin, the primary breast  
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fibroblast HMF, as well as a common metastatic tissue, the lung derived 
fibroblasts IMR90 and WI38 (Fig 2.1B and C). This phenotype once 
again scaled with fibroblast:cancer ratio, with tumor growth reaching only 50% of 
mono-culture in the 2:1 fibroblast:cancer ratio (Fig 2.1C).  
Next, I wanted to determine if co-culture of tumor cells with fibroblasts 
alters the drug response to the EGFR inhibitor erlotinib. Inhibition of EGFR 
impairs growth factor signaling and induces a cytostatic proliferation phenotype, 
as seen in BT20 and A549 tumor cell lines (Fig 2.1E). Subsequently, co-culture 
of tumor cells with fibroblasts generally had a neutral effect on cancer cell drug 
response, displayed as white, or a drug desensitization effect, displayed as red 
(Fig 2.1F). Fibroblast mediated desensitization to erlotinib varied by tumor cell 
line, with only the bone fibroblast Hs-5 and the brain fibroblast HBVAF 
desensitizing all 4 lines. The degree of erlotinib desensitization also varied 
between each fibroblast co-culture condition. The strongest desensitization 
phenotypes were observed from fibroblasts that were derived from either the 
brain, bone marrow, or lungs, all common sites of breast cancer metastasis. As 
seen with the proliferation phenotype, the degree to which erlotinib was inhibited 
depended on the fibroblast:cancer ratio (Fig 2.1G). 
 One of the strongest erlotinib desensitizing effects was observed in the 
lung cancer cell line A549 when co-cultured with the lung derived fibroblast 
IMR90 (Fig 2.2A). This was surprising as targeted EGFR inhibitors, such as  
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erlotinib, were developed and have been successful in treating non-small cell 
lung cancer (NSCLC) in patients that have mutations in EGFR. The observation 
that A549 is desensitized to erlotinib in a lung environment is concerning for the 
creation of patient therapies, so I wanted to investigate whether this phenotype 
was conserved among other lung cancer cell lines. I selected a panel of lung  
cancer cell lines, varying EGFR, KRAS, and p53 mutation status, to test the 
effect of fibroblast:cancer co-culture on erlotinib efficacy (Fig 2.2B). Once again 
co-culture with fibroblasts generally increased tumor cell proliferation compared 
to mono-culture, although the lung line H727 displayed a neutral effect that 
transitioned into inhibitory as the fibroblast:cancer ratio increased (Fig 2.2C). 
Fibroblast mediated altering of drug response was variable across the lung 
cancer cell lines (Fig 2.2D). Generally, co-culture with fibroblasts desensitized 
cancer cells to erlotinib. However, there was little to no effect observed in the 
lung lines H727 and H1650 (except in the lung environment), the only two lines 
that contained mutated p53 signaling. The greatest degree of erlotinib 
desensitization was observed in the co-culture conditions with either brain, bone 
marrow or lung derived fibroblasts. Importantly, the strong lung fibroblast 
mediated desensitization phenotype observed in the A549 cell line was not 
consistent across the expanded lung cancer cell line panel. The cell lines KP7B 
and H358 displayed a similar trend as A549, and both cell lines contained WT 
EGFR and p53. However, to determine if the lung specific desensitization to  
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erlotinib is significant or enriched in a subtype of lung cancer, the panel of lung 
cancer cell lines would have to be further expanded. 
After observing that the GFP assay was adept at measuring proliferation 
related phenotypes involving targeted agents, I wanted to test the assay’s 
sensitivity in capturing cell death in response to cytotoxic agents. Analysis of 
GFP microscopy images revealed that co-culture with the adrenal gland derived  
fibroblast HADF desensitized BT20 cells to the cytotoxic therapy camptothecin 
(Fig 2.3A and B). Interestingly, analysis of this same condition using a 
fluorescence plate reader failed to capture the difference in death between 
cancer cells in monoculture and co-culture to camptothecin (Fig 2.3C). In addition 
to not capturing the fibroblast influence on camptothecin sensitivity, plate reader‐
based analysis also failed to capture cell death, with all fluorescence 
measurements recording higher values than the initial pre‐drug measurement 
(Fig 2.3C). The inability of the plate reader-based approach to capture cell death 
was likely due to the stability of GFP fluorescence, which is still fluorescent even 
after the cells have died (Fig 2.3D). These data indicate that measuring GFP 
fluorescence using a fluorescence plate reader is not sensitive in quantifying the 
degree of cell death in a population of cells. 
 
Discussion: 
 In this chapter I explored the ability of a high-throughput assay utilizing 
GFP expressing cancer cells and a fluorescent plate reader to capture 
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proliferation and cell death phenotypes in an in vitro co-culture system. Using this 
GFP based assay, I was able to observe a pro-proliferation phenotype in both 
TNBC and lung cancer cell lines when co-cultured with primary fibroblasts in 
vitro. When comparing the proliferation phenotypes for one cancer cell line 
across the 8 fibroblasts conditions, there was a general pro-proliferation trend 
that lacked tissue specificity. This suggests that the mechanism that increases 
cancer cell growth is a general fibroblast feature and does not rely on tissue 
specific differentiation.  
Additionally, I demonstrated that co-culture of cancer cells with fibroblasts 
desensitizes cancer cells to the targeted EGFR inhibitor erlotinib. This is 
consistent with the overall finding from Golub and colleagues, which suggested 
that fibroblasts facilitate resistance to growth factor inhibition through secretion of 
growth factors49. Surprisingly, one of the strongest desensitizing environments, 
among the 4 cell lines tested in Fig 2.1F as well as among the different fibroblast 
environments, was the co-culture of A549 with the lung fibroblast IMR90. Despite 
this strong phenotype not being conserved across a variety of lung cancer cell 
lines, the observation of this tissue specific desensitization of A549 to erlotinib 
has clinical implications. Erlotinib was developed for the treatment of lung 
cancers and the observation that there are strong stromal specific interactions 
that lower the efficacy of the drug indicates that clinicians must treat patients on a 
case by case basis rather than prescribing one general therapy. Understanding 
these environmental interactions and discovering novel biomarkers to indicate 
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when the standard treatment of care will not be effective will dramatically 
increase our ability to treat cancer.  
Finally, my data showed that the GFP assay, which was proficient in 
identifying proliferation related phenotypes, could not accurately measure cell 
death. The stability of the GFP molecule inflates the fluorescent signal and does 
not decrease when a cell dies. When the wells were washed with PBS to remove 
any soluble GFP molecules, the GFP signal decreased. However, I noticed that 
the number of healthy cells attached to the plate had also decreased indicating 
that the wash step was too harsh. These data indicate that washing to remove 
GFP would not be viable in accurately measuring cell death. Given this, our data 
call into question prior studies that concluded that cytotoxic drugs are not 
affected by tumor-fibroblast interactions.  Future efforts will rely on the 
development of new high-throughput screening approaches to investigate the 
effects of fibroblast cancer cell interactions on cytotoxic chemotherapeutics. One 
potential fluorescent based assay that would be compatible with the plate reader 
would be the use of the mitochondrial membrane dye JC-1. JC-1 undergoes a 
fluorescent shift when the mitochondrial membrane becomes depolarized, one of 
the initial steps of apoptosis. This method is able to report cell death without 
relying on the degradation of a fluorescent molecule.  
 
Materials and Methods: 
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Cell lines and reagents 
Cell lines BT‐20, MDA‐MB‐231, MDA‐MB‐468, H358, H727, H1650, H1975, 
KP7B, A549, Hs-5, Hs27A, IMR90, WI38, and WS-1 were obtained from 
American Type Culture Collection (ATCC, Manassas, VA). All cell lines were 
grown in 10% FBS (Thermofisher Hyclone cat# SH30910.03 lot# AYG161519), 2 
mM glutamine, and penicillin/streptomycin. BT‐20, IMR90, WI38, and WS‐1 were 
cultured in Memα + Earle's salts. H358, H727, H1650, and H1975 were cultured 
in RPMI 1640 media. MDA‐MB‐231, MDA‐MB‐468, KP7B, Hs27A, and HS‐5 
were cultured in Dulbecco's modified Eagle's medium (DMEM). Primary 
fibroblasts HMF, HADF, and HBVAF were purchased from ScienCell (Carlsbad, 
CA). Primary fibroblast cells purchased from ScienCell were cultured in 
Fibroblast Medium (cat# 2301) for four doublings before being transitioned to 
DMEM. All cells were cultured at 37°C in a humidified incubator supplied with 5% 
CO2 and maintained at a low passage number (< 20 passages for cancer). Prior 
to expansion and freezing, a small sample of each primary fibroblast was 
expanded to determine each cell's Hayflick limit to ensure that experiments could 
be performed prior to the onset of replicative senescence. Erlotinib was 
purchased from LC Labs (cat# E-4007) and suspended at 10mM in DMSO 
 
Plate Reader Based GFP Assay 
To determine cell proliferation and cell death using a fluorescence plate reader, 
TNBC and Lung cancer cells were stably transfected with GFP (pRetroQ‐
32 
 
AcGFP1‐N1). Transfected cells were treated with puromycin and sorted to select 
for a pool of cells of similar GFP fluorescence. Cells were selected until a parallel 
non‐transformed plate exposed to puromycin was completely dead. For coculture 
experiments, fibroblast cell lines were plated at an 8:1, 4:1, 2:1, 1:1, and 1:2 ratio 
to cancer cells in a Greiner 96‐well plate in 100 μl of FluoroBrite media and 
allowed to adhere for 3 h. Following adherence of fibroblast cells, cancer cells 
constitutively expressing GFP were plated at a concentration of 5,000 cells per 
100 μl of FluoroBrite media and allowed to adhere overnight. Drug was added 
the next day and cell measurements were measured every 24 h for 96 h using a 
Tecan M1000 Pro Plate reader. 
 
Fluorescence microscopy 
For imaging of GFP‐labeled cells, cells were plated as describe in the plate 
reader methodology. Following drug exposure (various times as indicated in 
figures), images were collected using an EVOS FL‐AUTO automated 
fluorescence microscope. Analysis was performed using a custom CellProfiler 
pipeline. 
 
Data Availability: 
The CellProfiler script used for the analyses shown in Fig 2.3 can be viewed at 
DOI 10.15252/msb.20188322 as Code EV1.  
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CHAPTER III: Tumor‐stroma interactions differentially alter drug 
sensitivity based on the origin of stromal cells 
 
Chapter III was taken almost verbatim from:  
Landry BD, Leete T, Richards R, et al. Tumor‐stroma interactions differentially 
alter drug sensitivity based on the origin of stromal cells. Mol Syst Biol. 
2018;14(8):e8322. doi:10.15252/msb.20188322. 
 
Abstract: 
Due to tumor heterogeneity, most believe that effective treatments should 
be tailored to the features of an individual tumor or tumor subclass. It is still 
unclear, however, what information should be considered for optimal disease 
stratification, and most prior work focuses on tumor genomics. Here, we focus on 
the tumor microenvironment. Using a large‐scale coculture assay optimized to 
measure drug‐induced cell death, we identify tumor–stroma interactions that 
modulate drug sensitivity. Our data show that the chemo‐insensitivity typically 
associated with aggressive subtypes of breast cancer is not observed if these 
cells are grown in 2D or 3D monoculture, but is manifested when these cells are 
cocultured with stromal cells, such as fibroblasts. Furthermore, we find that 
fibroblasts influence drug responses in two distinct and divergent manners, 
associated with the tissue from which the fibroblasts were harvested. These 
divergent phenotypes occur regardless of the drug tested and result from 
modulation of apoptotic priming within tumor cells. Our study highlights 
unexpected diversity in tumor–stroma interactions, and we reveal new principles 
that dictate how fibroblasts alter tumor drug responses. 
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Introduction: 
A central challenge in medicine is selecting which drug or drug 
combination will be the most beneficial for a given patient. In cancer therapy, this 
decision has typically been based on the anatomical origin of the disease, in 
combination with drug screening to empirically identify the most efficacious 
compounds. In most cases, drug response rates vary considerably, and the 
causes of this response variability remain unclear. Thus, for ongoing efforts to 
improve precision/personalized medicine it is critical to identify features that 
contribute to the observed drug response variability. 
Several studies now exist that have explored the relationship between 
tumor genetics or tumor gene expression and drug response55–61. Many insights 
have been gained from these and other studies, but even collectively, these 
studies fail to create a clear understanding of the variable levels of sensitivity to 
commonly used chemotherapeutics62,63. An important consideration is that 
substantial non‐genetic heterogeneity exists within tumors, and these influences 
are generally missed in studies that focus exclusively on tumor genomics. For 
instance, several classes of normal cells typically reside within tumors. It is 
increasingly recognized that many tumor phenotypes, including tumor initiation, 
epithelial‐to‐mesenchymal transition (EMT), metastatic potential, and drug 
sensitivity, are influenced by interactions between cancer cells and the normal 
cells residing within or near tumors64,65. Prior studies have typically highlighted 
the variable and unpredictable nature of tumor–stroma interactions, in which the 
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drug sensitivity of cancer cells appears to depend on the particular combination 
of tumor cell, stromal cell, and drug used66. Thus, for efforts to improve precision 
medicine, a critical unmet need is to learn “rules” dictating how stromal cells 
influence the drug sensitivity of cancer cells. 
Here, we develop a mixed coculture assay optimized to specifically 
quantify cell death, rather than cell proliferation, and we use this assay to 
characterize functional interactions between tumor cells, stromal cells, and 
anticancer chemotherapeutic agents. We report that stromal fibroblasts influence 
tumor drug response in two distinct and divergent manners: Some interactions 
result in drug resistance, while others cause drug sensitization. Importantly, 
these divergent influences were associated with the anatomical tissue from which 
the fibroblasts were harvested. Surprisingly, our data show that these distinct 
fibroblast‐dependent phenotypes are conserved regardless of the identity or 
molecular target of the drug. These broad‐spectrum changes to drug sensitivity 
result from modulation of mitochondrial apoptotic “priming”, which changes the 
threshold for initiation of apoptosis in cancer cells. Taken together, our study 
highlights previously unappreciated principles, which dictate how stromal 
fibroblasts alter a tumor cell's drug response. 
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Results: 
Cell‐intrinsic sensitivity to commonly used chemotherapy is similar for 
basal‐like and mesenchymal‐like TNBC cells. 
To explore cell non‐autonomous regulation of drug sensitivity, we began 
by focusing on a tumor subclass that displays notable response heterogeneity, 
without clear mechanisms that underlie these differences. “Triple‐negative” 
breast cancers (TNBCs) are the most chemosensitive subtype of breast cancer, 
but also the subtype with the shortest disease‐free survival and lowest overall 
survival rates67,68. This paradox is thought to result from heterogeneity within the 
TNBC subclass69. Additionally, although TNBC can be further stratified into 
several definable groups which differ in chemosensitivity69, it remains unclear 
which features are responsible for creating the variable drug sensitivity that is 
observed clinically. 
To highlight this variability in the drug response, we selected a panel of 
ten TNBC cells from either the “basal‐like” or “mesenchymal‐like” expression 
classes69–71. Basal‐like (BL) cells—sometimes referred to as “basal A”, “basal‐like 
1”, and “basal‐like 2”—are defined by expression of basal or myoepithelial genes. 
These cells are highly proliferative, tend to have elevated expression of DNA 
damage response genes, and generally respond at higher rates to cytotoxic 
chemotherapies in vivo69. Mesenchymal‐like (ML) TNBCs—which includes 
“mesenchymal”, “mesenchymal stemlike”, and “claudin‐low” expression 
classes—are enriched for expression of genes related to EMT, and genes 
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associated with stemness. These cells are more “aggressive” clinically, more de‐
differentiated, more metastatic, and more chemoresistant in vivo69,72. Thus, we 
initially reasoned that identifying mechanisms which account for the variability in 
DNA damage sensitivity between the BL and ML subclasses may aid in patient 
stratification or help to identify new strategies for improving responses to these 
agents. 
To identify features that contribute to differential DNA damage sensitivity 
between BL and ML cells, we began by profiling the response of TNBC cells to 
doxorubicin (also called Adriamycin), a topoisomerase II inhibitor that is 
commonly used in the treatment of TNBC. We suspected that if the observed 
clinical patterns of aggressiveness were due to intrinsic differences in drug 
sensitivity associated with these gene expression states, different levels of 
sensitivity to doxorubicin should be observed in vitro. Indeed, the least sensitive 
cells were HCC‐1395, a TNBC of the ML expression state; the most sensitive 
cells were MDA‐MB‐468, a TNBC in the chemosensitive BL category (Fig 3.1A). 
In contrast, however, the rest of the cell lines tested were similarly sensitive to 
doxorubicin, regardless of their gene expression state. To see whether this was 
unique to doxorubicin, we also profiled responses to other topoisomerase 
inhibitors in this panel of cells. Overall, these data reveal relatively similar levels 
of drug sensitivity across these 10 cell lines (Fig 3.2A). To more rigorously 
determine whether the patterns of sensitivity to these drugs could be used to 
distinguish BL versus ML cells, we performed hierarchical clustering using either 
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the EC50 or the maximum effect observed for each drug. This analysis also 
failed to correctly separate BL and ML cells based on their observed drug 
sensitivity profile (Fig 3.1B and Fig 3.2B). 
The results from our in vitro analysis suggest that these BL and ML cells 
have similar sensitivity to commonly used chemotherapeutics. This, of course, is 
not in line with the expected observation that ML tumors respond at lower rates 
than BL tumors in vivo73. One explanation could be bias within our samples, as 
our dataset was comprised of a relatively small number of TNBCs. To address 
this, we also analyzed data publicly available through the LINCS consortium, 
which include drug sensitivities for a larger panel of 24 BL or ML cell lines (11 BL 
and 13 ML) and a larger panel of common anticancer drugs74. These data also 
show that BL and ML cells have similar levels of sensitivity to topoisomerase 
inhibitors, specifically, or to all anticancer drugs, generally (Fig 3.1C and Fig 
3.2D). Thus, taken together, these data highlight that the subtype‐dependent 
differences in drug sensitivity, which may be expected given responses observed 
in patients, are generally not observed when these cells are grown in standard in 
vitro cell culture conditions. 
Another potential explanation for the discrepancy between our data and 
the relative drug sensitivities that were expected could be that our cells were 
grown in 2D, rather than using 3D culturing conditions. It has generally been 
found that many cell behaviors differ when cells are grown in 2D versus 3D, and 
that 3D culture is in many ways a more accurate representation of the in vivo 
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environment75,76. To test whether growth in 3D recapitulates the expected 
distinction between BL and ML cells, we retested sensitivity to 10 topoisomerase 
inhibitors for TNBC cells grown as 3D colonies in a Matrigel growth environment. 
Growth of these TNBC cells in 3D colonies strongly altered drug sensitivity (Fig 
3.1D). In some cases, a modest trend was observable in which ML cells appear 
less sensitive to drugs (e.g., camptothecin), but these trends were not statistically 
significant. The dominant trend was an overall desensitization to these drugs, 
without further refining the distinction between BL and ML cells (P > 0.05 for all 
drugs in 2D and 3D culture; Fig 3.1D and Fig 3.2C). This finding is consistent 
with prior studies, which demonstrated that growth in 3D induces a general 
resistance to drug‐induced apoptosis77. Thus, taken together, our data highlight 
that these BL and ML TNBC cells are similarly sensitive to commonly used 
chemotherapeutics, at least when cultured in standard 2D or 3D monoculture 
conditions. This finding raises the possibility BL and ML subtype‐specific 
responses to treatment are not cell‐intrinsic properties, but rather a product of 
subtype‐specific interactions between tumor cells and microenvironmental 
features. 
 
Coculture screen optimized to monitor cell death reveals widespread 
stromal influence on TNBC drug sensitivity. 
Based on the results of our in vitro drug screen of TNBC cells grown in 
monoculture, we aimed to test the hypothesis that differences between the 
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chemosensitivity of BL and ML cells are induced, in part, by cell non‐autonomous 
influences. Several studies have suggested that interactions between tumor cells 
and components of the tumor microenvironment—including extracellular matrix, 
growth factors, and other stromal cell types—can alter sensitivity to 
chemotherapy49,77,78. We focused on interactions between cancer cells and 
stromal fibroblasts, which are often the predominant stromal type found within the 
tumor microenvironment79. 
To identify tumor–stroma interactions that alter drug response, we initially 
tested an in vitro coculture system that was successfully used to evaluate tumor–
stroma–drug interactions49 (Fig 2.3C and D). However, these data indicate that 
measurements of GFP fluorescence using a fluorescence plate reader were not 
sufficiently sensitive for quantifying the degree of cell death in a population of 
cells. Based on these results, we modified our coculture screen to optimize 
measurement of drug‐induced cell death. We used JC‐1, a dye that accumulates 
within mitochondria and is often used as a surrogate measure of apoptotic cell 
death80 (Fig 3.3A and B). At low concentrations, JC‐1 exists as a monomer and 
yields green fluorescence; however, when accumulated at high concentrations 
within mitochondria, this dye forms aggregates, which yield red fluorescence. 
Thus, the red fluorescence of JC‐1 reports cellular mitochondrial integrity, which 
is lost when cells activate apoptosis. To assess the suitability of JC‐1 to quantify 
changes in the degree of cell death in coculture, we again piloted this assay on 
BT‐20 cells treated with camptothecin in the presence or absence of HADF. 
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Images of these cells taken prior to drug exposure confirm punctate red 
fluorescence in BT‐20, but not HADF, confirming that the dye is not exchanged 
between cells in coculture (Fig 3.3B). 96 h after exposure to camptothecin, the 
majority of BT‐20 cells had significantly reduced JC‐1 red fluorescence, 
suggesting that mitochondrial integrity has been compromised (Fig 3.3C). 
Importantly, JC‐1 red fluorescence measured using a fluorescence plate reader 
was sufficiently sensitive for observing both the potent cell death of BT‐20 cells in 
monoculture and the protective effect of HADF cells in coculture (Fig 3.3D). 
To evaluate the role of stromal fibroblasts in DNA damage sensitivity, we 
selected six TNBC cell lines (three BL and three ML) that have relatively similar 
levels of sensitivity to DNA damage. These JC‐1‐labeled TNBC cells were grown 
in monoculture or in coculture with each of a panel of 16 primary human 
fibroblasts. Each culture was exposed to a four‐point dose range of 42 anticancer 
drugs, which included at least one drug per class for all current FDA‐approved 
breast cancer drugs (Tables 3.1 and 3.2). JC‐1 red fluorescence was quantified 
at 8‐hour intervals for 72 hours. In total, we collected more than 300,000 
measurements of drug sensitivity (Fig 3.3E, Fig 3.4A–C, and Table 3.3). We 
found a strong overall correlation among biological replicates, indicating that the 
stromal influences observed were not due to measurement noise (Fig 3.4D). To 
identify TNBC–fibroblast interactions that significantly altered sensitivity, we used 
a statistical fold‐change cutoff of 3× the standard deviation observed among 
replicates. This analysis identified 5,039 significantly changed drug responses 
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(Fig 3.4E). As may be expected, this list of “hits” was significantly depleted for 
responses at early times (i.e., 8 h), low doses (0.1 μM), and responses to anti‐
estrogen drugs (Tables 3.3 and 3.4). Non‐response to anti‐estrogen compounds 
is expected as TNBCs do not express estrogen or progesterone receptors. 
The majority of TNBC cell–fibroblast interactions did not alter drug 
sensitivity (Fig 3.4A–C). Nonetheless, our screen revealed many striking 
phenotypes of strongly altered drug responses, and overall, our data cover nearly 
the entire landscape of possible positive and negative interactions (Fig 3.3E). To 
determine the reliability of these measurements, we selected a subset of these 
interactions to validate by flow cytometry. For example, our screen identified that 
palbociclib killed more than 80% of HCC‐1143 cells, a basal‐like TNBC, if applied 
to these cells in monoculture. However, this drug was rendered ineffective when 
HCC‐1143 cells were cocultured with the fibroblast cell, HCPF, resulting in only a 
20–40% decrease in cell viability (orange dots, Fig 3.3E). A flow cytometry‐based 
analysis of cell death recapitulated this drug desensitization phenotype (Fig 3.3F 
and G). Additionally, our coculture screen identified instances in which the 
efficacy of etoposide is significantly improved in coculture conditions. For 
example, etoposide was ineffective in killing mesenchymal‐like Hs578T cells in 
monoculture but killed more than 50% of these cells grown in coculture with skin 
fibroblast cells, WS1 (purple dots, Fig 3.3E). This phenotype was interesting 
because prior studies have found that etoposide is minimally active in 
monoculture, which was surprising given the clinical utility of this compound54. 
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Flow cytometry‐based analysis of cell death confirmed that etoposide‐induced 
cell death in Hs578T is significantly enhanced by coculture with WS1 fibroblasts 
(Fig 3.3H and I). Thus, our coculture drug screen identified a spectrum of TNBC–
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fibroblast interactions that modulate the drug response of TNBC cells in both 
positive and negative directions (Figs 3.5–3.7). 
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Primary fibroblasts grown in coculture with TNBC cells display an activated 
phenotype and modulate drug sensitivity similar to cancer‐associated 
fibroblasts (CAFs). 
Our coculture drug screen was comprised mainly of normal primary 
fibroblasts. Cancer‐associated fibroblasts (CAFs, also called “activated” 
fibroblasts, myoepithelial cells, or myofibroblasts) are thought to be largely 
distinct from primary fibroblasts in their ability to promote aspects of 
tumorigenesis and tumor progression43,64. Thus, to address the relevance of our 
findings we also aimed to compare the behaviors of primary fibroblasts and 
CAFs, and in particular, the ability of these different cell types to modulate drug 
responses of TNBCs in coculture. We first asked whether our primary fibroblasts 
adopt an activated phenotype in culture. Prior studies have found that the 
unnatural environmental stiffness of in vitro culture can cause primary fibroblasts 
to spontaneously adopt the activated phenotype81. Using immunofluorescence 
microscopy, we determined α−smooth muscle actin (SMA) expression in 
fibroblasts, a marker of the activated fibroblast expression state that is commonly 
observed in CAFs. Robust but variable SMA positivity was observed for all 
primary fibroblasts tested (Fig 3.8A). To more precisely quantify percentages of 
SMA+ fibroblasts, and to determine whether coculture modulated SMA positivity, 
we measured the percent of SMA+ cells using flow cytometry (Fig 3.8B). The 
percentage of SMA+ fibroblasts was relatively high, even when fibroblasts were 
grown in monoculture (median 63%; range 10–85%), and was consistently  
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increased when fibroblasts were cocultured with TNBC cells (Fig 3.8C). Thus, 
primary fibroblasts grown in coculture with TNBC cells generally adopt the 
activated expression state that is commonly observed for CAFs. 
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To compare the degree to which primary or CAF cells modulate drug 
sensitivity of TNBC cells, we repeated a small portion of our coculture drug 
screen using one primary mammary fibroblast (HMF) and two breast cancer‐
associated fibroblasts (Hs343T and Hs578BST). Overall, the drug 
sensitization/desensitization profile revealed a similar pattern of relative drug 
sensitivity when compared to our initial coculture screen (Fig 3.8D). Additionally, 
primary and CAF cells modulated sensitivity to common anticancer drugs in a 
significantly correlated manner (r = 0.46; P < 0.0001). This suggests that, 
although primary fibroblasts and CAFs likely differ in many substantial ways, 
these different cell types were similar in the manner in which they alter drug 
sensitivity of associated cancer cells. This finding is consistent with a previous 
study by Polyak and colleagues, which found that patient‐derived primary or CAF 
cells from breast or brain specimens similarly desensitized HER2‐positive breast 
cancer cells to the HER2 inhibitor lapatinib39. 
 
TNBC–fibroblast interactions are sufficient for inducing differential drug 
sensitivity between basal‐like and mesenchymal‐like TNBCs. 
Our profiling of TNBC cell lines grown in 2D or 3D monoculture failed to 
identify robust differences in the drug sensitivities between BL and ML cells (Fig 
3.1). Since our coculture screen revealed strong positive and negative changes 
in the drug responses of these cells (Figs 3.5–3.7), we asked whether these 
altered drug sensitivity profiles improved the resolution between BL and ML cells. 
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To test this, we performed principal component analysis (PCA) on our coculture 
screening data. We reasoned that PCA would be beneficial due to the high 
dimensionality of our data (i.e., multiple drugs, cells, coculture environments, 
doses, times). PCA uses the covariation structure of the data to reduce data  
 
dimensionality to a smaller number of “principal components”, with each 
component being comprised of related information82. 
Principal component analysis of our coculture data reduced these complex 
observations to 10 principal components, with the first two components capturing 
53% of the overall variation in drug sensitivity (Fig 3.9A). The projection of our 
data onto PC1 and PC2 revealed a clear separation of BL and ML cells (Fig 
3.10A). Notably, this expected pattern was not visible in drug response data 
collected on these TNBC cells grown in monoculture (Figs 3.1B and 3.10B). 
Thus, our screening data reveal that coculture of TNBCs with fibroblast cells 
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modulates drug sensitivity in a manner that enhances the distinction between BL 
and ML cells. 
Because each principal component captures unrelated/orthogonal 
variation in the data, we also sought to determine which components were 
capturing variation associated with the BL/ML dichotomy. For example, the 
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BL/ML distinction could be captured independently on all PCs. This would 
suggest that BL and ML cells respond differently to all drugs, in all coculture 
environments. Alternatively, it is also possible that the BL/ML distinction is 
restricted to one or a few PCs, suggesting that BL and ML cells respond in 
distinct ways only in the context of a subset of drugs and/or environmental 
conditions. Thus, to investigate this further, we quantified the degree of 
separation of BL/ML cells across all 10 PCs (Fig 3.10C). A strong association 
was identified for PC2, which captured approximately 13% of the data. Modest 
but significant associations with BL/ML were also found for PC3, 5, and 6, which 
each of which captured relatively small amounts of the dataset (Fig 3.9B). Thus, 
we focused on finding features in our data that were driving the association 
between PC2 and BL/ML cells. To achieve this, we inspected the PCA vector 
loadings, which report the degree to which each variable contributes to a given 
component. We noticed strong positive loading coefficients on PC2 for 
conventional chemotherapeutics, such as etoposide and paclitaxel (Fig 3.10D). 
To determine whether these observations were statistically robust, we quantified 
the statistical enrichment of each class of drugs on PC2, finding the strongest 
enrichments for topoisomerase inhibitors and microtubule poisons, two drug 
classes that are commonly used in the treatment of breast cancer (Fig 3.10E). 
We selected a subset of drugs to re‐evaluate that had strong positive loading 
coefficients on PC2, suggesting that BL and ML cells would have clearly distinct 
responses to these drugs. Consistent with these PCA generated insights, we 
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found that BL cell sensitivity and ML cell sensitivity to etoposide and paclitaxel 
were clearly distinct in coculture, but not in monoculture, with BL cells generally 
being more sensitive to these conventional chemotherapies (Fig 3.10F and G). 
Taken together, these data demonstrate that coculture with fibroblasts was 
sufficient to enhance distinctions between BL and ML TNBC cells. 
 
Divergent interactions between TNBCs and fibroblasts based on the 
anatomical origin of fibroblast cells. 
Our coculture screen identified environmentally modulated drug responses 
that differed between BL and ML subtypes of TNBC. Notably, however, these 
distinctions were seen only for a small fraction of the drug responses tested in 
our screen, and primarily only in the context of drugs that are currently used in 
the treatment of TNBC. This distinction suggests that most of the response 
variation found in our screen is not associated with the BL/ML dichotomy and that 
opportunities may be found in our dataset that sensitize both BL and ML cells to 
conventional chemotherapeutics. Thus, we reasoned that deeper insights into the 
other sources of drug response variation in our data may reveal new strategies 
for potentiating drug responses in TNBC. PC1, which captured approximately 
40% of the overall variation in drug sensitivity, was revealing a dominant pattern 
in our data that is unrelated to the BL/ML dichotomy (Fig 3.10A). To gain a 
deeper understanding of the sources of drug response variability in our data, we 
focused on identifying features of our data that were associated with PC1. We 
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observed a noticeable clustering on PC1 for scores related to each fibroblast cell 
type (Fig 3.11A and Fig 3.12). To determine whether this pattern was revealing 
fibroblast cell‐specific, or fibroblast tissue‐specific variation, we computed the 
correlation between fibroblasts from the same tissue, versus between fibroblasts 
derived from different tissues. We found a significantly higher correlation 
between fibroblasts that were derived from the same anatomical tissue (Fig 
3.11B and Fig 3.12). These data suggest that fibroblasts harvested from the 
same tissue modulate the drug responses of associated TNBC cells in similar 
ways. 
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Fibroblasts from different tissues could be modulating one of several 
aspects of TNBC drug response, including the response rate, magnitude of 
response (e.g., Emax or EC50), or the directionality of the influence (e.g., 
increased or decreased sensitivity). Because our dataset included a surprising 
level of directional variability in fibroblast influence, we began by asking whether 
the directional variance in our screen could be attributed to distinct directionally 
specific influences of fibroblast from different tissues (i.e., Is a fibroblast from a 
given tissue intrinsically more likely to induce drug sensitization/de‐
sensitization?). To test this, we calculated the ratio of drug responses for each 
TNBC–drug combination, in coculture versus monoculture. To facilitate visual 
inspection of the relative influences induced by each fibroblast type, we 
organized the data by dose and time, in order to highlight conserved fibroblast‐
dependent influences (Fig 3.11C). Each data tile was then subsequently grouped 
by stromal location and drug, and a map of this type was created for each TNBC 
cell line. From this analysis, clear differences between fibroblast lines were 
visible, with each fibroblast promoting either drug sensitization or desensitization 
(Fig 3.11D). These patterns were similar between BL and ML subtypes, although 
ML TNBCs had more strongly polarized responses, in both positive and negative 
directions (Fig 3.11E). Some drug‐specific responses, such as the 
desensitization of TNBCs to sunitinib, occurred regardless of which fibroblast 
was used in coculture. Interestingly, however, these drug‐specific interactions 
were rare, and most fibroblast‐induced changes in drug sensitivity were observed 
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in a similar manner, across essentially all drugs, and in both BL and ML subtype 
TNBCs. Thus, rather than finding unpredictable or idiosyncratic interactions, 
specific to precise TNBC–fibroblast–drug combinations, our analysis reveals a 
dominant and relatively straightforward pattern: Fibroblasts modulate the drug 
response of TNBC cells in distinct and divergent manners, which are largely 
dependent on the anatomical origin from which the cells were harvested. 
 
Fibroblast‐dependent, and drug‐independent, variation in drug sensitivity 
occurs through modulation of the mitochondrial apoptotic priming state of 
TNBC cells. 
An unexpected phenotype from our screen was the degree to which a 
given fibroblast's influence over TNBC drug sensitivity was consistent regardless 
of which drug was applied (Fig 3.11D and E). Thus, we next aimed to determine 
the mechanism by which fibroblasts could interact with TNBC cells to produce 
these divergent—and largely drug identity independent—changes in TNBC drug 
response. The simplest mechanism that is consistent with this observation would 
be that these fibroblasts cause a direct modulation of TNBC cell growth or 
survival, independent of the drugs added (Fig 3.13, example I and Fig 3.14A). To 
test this, we used GFP‐tagged TNBC cells to monitor TNBC‐specific 
growth/survival phenotypes, in the absence of any drug. We found that most 
fibroblast cells either did not alter the growth rate of TNBC cells, or induced a 
modest growth rate increase in TNBC cells grown in coculture (Fig 3.14B).  
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Furthermore, in the context of fibroblasts that consistently sensitized drug 
response of all TNBC cell lines (e.g., WS1, C12385, or HUF), coculture did not 
significantly decrease growth or survival, suggesting that a growth fitness or 
survival defect does not account for the broad‐spectrum drug sensitization seen 
in coculture with these cells. In rare instances, coculture conditions did result in a 
significant TNBC cell growth rate decrease, such as seen with MDA‐MB‐231 
cells grown with H6013, a fibroblast derived from lung tissue (Fig 3.14B). 
Notably, the M231‐H6013 interaction induced broad‐spectrum drug 
desensitization (i.e., enhanced survival). Thus, even in the rare instances in  
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which fibroblast cells mediated fitness defects, growth rate or survival modulation 
does not appear to account for the observed pattern of influences on TNBC drug 
response. 
A second mechanism by which fibroblast cells could enhance drug 
efficacy could be by modulating drug bioavailability (Fig 3.14A, example ii). This 
could be achieved, for example, if fibroblast cells altered the levels of expression 
of drug efflux pumps in cancer cells, if fibroblasts sequestered drugs, or if 
fibroblasts metabolized the drugs, creating a more/less potent or bioavailable 
compound (Fig 3.13). This latter mechanism was recently reported to explain a 
microbiome–drug interaction that modulates toxicity of the chemotherapeutic 5‐
FU29. To test the role of fibroblast modulation of drug metabolism or availability, 
we focused on drugs that activate death through induction of DNA damage. For 
this set of compounds, drug potency should be proportional to level of γ−H2AX, 
which marks sites of DNA double‐stranded breaks. We quantified γ−H2AX 
nuclear intensity following exposure to DNA‐damaging agents, in the presence 
and absence of fibroblasts. These measurements were made at four time points 
following exposure to 1 μM teniposide, cisplatin, etoposide, or camptothecin. We 
used GFP‐labeled TNBC cells to identify TNBC cell nuclei, and images were 
quantified using a CellProfiler‐based automated image analysis83 (Fig 3.14C). 
We began by inspecting the most strongly sensitizing and desensitizing coculture 
environments to determine whether these extreme cases could be explained by 
differences in the apparent drug potency. TNBC nuclear γ−H2AX intensity was 
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similar in BT‐20 cells grown in monoculture or when cocultured with C12385, a 
uterine fibroblast that strongly sensitized TNBC drug response (Fig 3.14D). 
Similarly, differences in γ−H2AX between mono‐ and cocultures were also not 
observed when BT‐20 cells were cocultured with Hs27A, a bone fibroblast that 
strongly desensitized drug responses (Fig 3.14E). To more comprehensively 
determine whether modulation of drug potency could account for the observed 
pattern of drug sensitization/de‐sensitization, we compared these changes in 
γ−H2AX intensity from quantitative image analysis, to the relative changes in 
drug sensitivity from our coculture screen. Overall, there was a low correlation 
between the degree to which γ−H2AX was modulated by fibroblasts and the 
phenotypic influence of these fibroblasts, which was not significant when 
compared to a randomized dataset (r = 0.134, P > 0.05; Fig 3.14F). Thus, it does 
not appear that fibroblast influences on drug sensitivity generally occur through 
modulation of drug availability or potency. 
The insights gained from γ−H2AX intensity analysis are also consistent 
with our general observation that fibroblast cells influence drug sensitivity in 
similar ways across diverse and unrelated classes of drugs. In other words, it 
does not appear that the mechanisms by which fibroblast cells influence the drug 
responses in TNBC cells are specific to the drug compounds themselves or drug‐
specific responses of TNBC cells. Drug‐induced cell death is the product of at 
least two independent influences: the drug‐specific cell response (i.e., the ability 
of a drug to change a cell from a healthy to a dead state) and the degree to 
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which the cell is “primed” for death (i.e., how “close” the healthy cell is to 
dying)80,84. Thus, a third mechanism that we tested was whether fibroblasts alter 
the degree of mitochondrial apoptotic priming (Fig 3.13A, example iii). The state 
of apoptotic priming is thought to relate to the relative local concentration of pro‐ 
and anti‐apoptotic proteins on the surface of mitochondria85. Thus, the priming 
state of a cell is not easily determined from gene or protein expression levels, but 
relative changes in priming can be empirically determined using the BH3 profiling 
technique86. This assay was recently used to demonstrate that normal or cancer‐
associated fibroblasts (CAFs) from mammary and brain tissue induce resistance 
to the HER2 inhibitor, lapatinib, in HER2 overexpressing breast cancers39. 
Similarly, mammary‐ and brain‐derived fibroblast also induced desensitization to 
lapatinib in our screen (Fig 3.11D). Thus, we used the BH3 profiling assay to 
assess the degree to which fibroblasts alter the mitochondrial priming state of 
TNBC cells. We selected five fibroblast cells that produced the strongest and 
most consistent modulation of drug sensitivity. The mitochondrial response to 
BIM peptide was quantified by monitoring cytochrome c retention within cancer 
cells by flow cytometry (Fig 3.14G). BH3 profiling revealed that fibroblast 
coculture significantly altered the mitochondrial priming state in both basal‐like 
(BT‐20) and mesenchymal‐like (MDA‐MB‐231) TNBC cells (Fig 3.14H and I). 
Furthermore, the degree to which mitochondrial priming was increased or 
decreased was also highly correlated with relative drug sensitivity observed in 
our coculture screen (Fig 3.14I). Thus, in instances where fibroblasts strongly 
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alter broad‐spectrum drug sensitivities of TNBC cells, both the positive and 
negative changes in drug sensitivity are induced by modulation of mitochondrial 
priming. 
We next aimed to determine whether the fibroblast‐induced changes in 
TNBC mitochondrial priming translated to different levels of sensitivity to drugs 
designed to modulate the apoptotic threshold. For example, BH3 mimetic drugs 
function by inhibiting anti‐apoptotic proteins, such as BCL2 and other related 
family members. Because these agents inhibit apoptotic inhibitors, but do not in 
and of themselves generate pro‐apoptotic activating signals, their efficacy relies 
on the native priming state of cancer cells87. Thus, we reasoned that fibroblasts 
that enhance or suppress the priming state of cancer cells may differentially alter 
sensitivity to BH3 mimetic drugs. To test this, we exposed GFP‐labeled BT‐20 
cells to varying concentrations of the topoisomerase II inhibitor teniposide and/or 
ABT‐737, a broad‐spectrum BCL2 family inhibitor. Images were collected 
following 48 hours of drug exposure (Fig 3.15A). To quantify cells, we used a 
CellProfiler‐based automated image analysis. Contrary to what is commonly 
seen for many hematopoietic cancers, ABT‐737 did not kill BT‐20 cells when 
applied as a single agent (Fig 3.15B, top); however, combinations of ABT‐737 
and teniposide were generally synergistic when applied to BT‐20 cells grown in 
monoculture (Fig 3.15C, top). The synergistic interaction between ABT‐737 and 
teniposide was further enhanced when BT‐20 cells were grown in coculture with 
C12385, a uterine fibroblast that enhanced apoptotic priming (Fig 3.15B and C, 
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middle). In contrast, when BT‐20 cells were grown in coculture with HADF, an 
adrenal fibroblast that potently decreased apoptotic priming, the drug synergy 
between these two agents was largely blocked, with most dose combinations 
resulting in additivity, or even modest drug antagonism (Fig 3.15B and C, 
bottom). These data confirm the role of fibroblasts in modulating apoptotic 
72 
 
priming of associated tumor cells. Additionally, our data demonstrate that tumor–
stroma interactions have the capacity to modulate, not only drug sensitivity, but 
also drug–drug interactions, further highlighting that these interactions are critical 
features that dictate how cancer cells respond to drugs. 
 
Discussion: 
In this study, we explored interactions between tumor cells and stromal 
cells to identify those that modulate sensitivity to commonly used 
chemotherapeutics. We found that fibroblasts alter drug sensitivity of tumor cells, 
and that the responses were highly variable, both in magnitude and in direction. 
Our statistical analysis clarified that the directional variability in fibroblast 
influence is predominantly associated with the anatomical tissue from which the 
fibroblast cells were harvested. This is an important observation, particularly 
considering that prior studies have typically only observed that stromal influences 
were unpredictable and/or very specific to the particular tumor–fibroblast–drug 
combination66. Surprisingly, we found that fibroblast‐dependent changes in drug 
response were consistently observed, regardless of which drug was applied, 
which was driven by fibroblast‐dependent modulation of mitochondrial apoptotic 
priming within cancer cells. 
A major surprise from our work is the substantial directional variability in 
fibroblast influence and in particular the large proportion of tumor–fibroblast 
interactions that result in drug sensitization. Prior studies that have interrogated 
73 
 
fibroblast–tumor cell–drug interactions have found that these interactions 
generally result in drug resistance, with only rare instances in which stromal cell 
interactions lead to drug sensitization39,49,66. The differences observed in our 
screen likely resulted, in part, from the experimental scale used in our study. For 
example, some recent smaller scale studies have concluded that fibroblasts 
induce therapeutic resistance regardless of their tissue of origin39. As noted 
above, our study successfully replicated the drug resistance phenotypes found in 
prior studies, and in our data, these drug resistance phenotypes are found in the 
context of many drug‐sensitizing phenotypes that were not previously tested. An 
additional possibility is that our screening methodology, which was designed to 
exclusively monitor drug‐induced cell death, contributed to the enhanced 
resolution of cell death sensitization. In fact, this feature is likely to have played a 
major role, considering the limited ability of other common approaches to quantify 
differences in the degree of cell death (Fig 2.3). A third possibility is that 
fibroblast‐mediated drug sensitization is a more common phenotype in TNBC, as 
this cancer subtype was not deeply profiled in prior studies. A focused 
interrogation of other cancer subtypes may help to determine the extent to which 
fibroblast influences vary across different cancers. 
Taken together, the findings from our study have potentially important 
implications that warrant consideration in the context of “personalized” or 
“precision” medicine, particularly for efforts to improve efficacy of commonly used 
therapies, such as cytotoxic chemotherapies or other pro‐apoptotic agents. For 
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instance, as we did not see differences in chemosensitivity between BL and ML 
cells grown in monoculture, it is possible that differences in chemosensitivity 
between these subtypes of TNBC may not be cell‐intrinsic features, but instead 
may be the product of interactions between these cells and stromal cells. Thus, it 
is unclear whether detailed studies on the genomics of TNBC cells will be 
informative for identifying strategies to enhance chemosensitivity. Additionally, 
our experiments exploring the efficacy of BH3 mimetic compounds in 
combination with conventional chemotherapy reveal that the nature of drug–drug 
interactions (i.e., synergy or antagonism) depends strongly on the growth 
environment and not only on the cancer genotype. Furthermore, our ability to 
predict this drug–drug–environment interaction was facilitated by a mechanistic 
understanding of how fibroblasts modify drug responses in TNBC cells. Thus, 
future efforts to predict effective drug combinations in vivo will likewise require a 
greater understanding of how stromal cells from different tissues modulate the 
drug sensitivity of cancer cells. 
Our findings highlight two potentially new opportunities to improve 
therapeutic responses in TNBC. First, our data show that the relative drug 
insensitivity of ML subtype TNBCs is restricted to only a few drug classes, which 
were generally strong apoptotic agents that are commonly used in treatment 
today. The drug specificity of the BL/ML dichotomy suggests that opportunities 
may exist for improving the responses of ML subtype cancers, perhaps in the 
context of other classes of drugs. Indeed, some drugs—which were equally 
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efficacious in BL and ML cells grown in monoculture—were in fact more effective 
in the ML subtype when these cells were grown in coculture (see for example, 
bortezomib, Fig 3.11D). The ability to directly test these hypotheses in vivo is 
currently limited, as coculture xenograft models typically require the use of 
external matrix (e.g., Matrigel) to support the implantation of fibroblasts, which 
obscures the tumor–fibroblast interaction (Fig 3.16). Second, the strong drug‐ 
 
independent influences of fibroblasts suggest that a more generalizable strategy 
may be to block interactions with drug desensitizing fibroblasts or to mimic the 
interactions of drug‐sensitizing fibroblasts. Future studies should therefore aim to 
gain a comprehensive understanding of the mechanisms of interaction between 
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fibroblasts and cancer cells, and in particular, the mechanisms by which 
fibroblasts alter the priming state of cancer cells. 
 
Materials and Methods: 
 
Cell lines and reagents 
Cell lines BT‐20, HCC‐1143, Hs578T, Hs578BST, MDA‐MB‐231, MDA‐MB‐436, 
MDA‐MB‐468, HCC‐2157, HCC‐1806, HCC‐1395, Hs27A, HS‐5, WI‐38, IMR‐90, 
Hs343T, WS‐1 were obtained from American Type Culture Collection (ATCC, 
Manassas, VA), and cell line CAL‐120 was obtained from Deutsche Sammlung 
von Mikroorganismen und Zellkulturen GmbH (DSMZ). All cell lines were grown 
in 10% FBS (Thermofisher Hyclone cat# SH30910.03 lot# AYG161519), 2 mM 
glutamine, and penicillin/streptomycin. BT‐20, CAL‐120, and WS‐1 were cultured 
in Memα + Earle's salts. HCC‐1143, HCC‐2157, HCC‐1806, and HCC‐1395 were 
cultured in RPMI 1640 media. Hs578T, MDA‐MB‐231, MDA‐MB‐436, MDA‐MB‐
468, Hs27A, HS‐5, and Hs343T were cultured in Dulbecco's modified Eagle's 
medium (DMEM). Hs578T was further supplemented with 10 μg/ml insulin. 
Hs578BST was supplemented with 30 ng/ml EGF. Primary fibroblasts, H‐6231, 
H‐6201, H‐6076, H‐6019, and H‐6013, were purchased from Cell Biologics 
(Chicago, IL); HCPF, HPF‐a, HHSteC, HMF, HAdF, HUF, and HCF‐a were 
purchased from ScienCell (Carlsbad, CA); and C‐12385 was purchased from 
Promocell (Heidelberg, Germany). Primary fibroblast cells purchased from Cell 
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Biologics, ScienCell, and Promocell were cultured in the media (ScienCell—
Fibroblast Medium cat# 2301; Cell Biologics—Complete Fibroblast Medium/w Kit 
cat# M2267; Promocell—Fibroblast Growth Medium 2 cat# C‐23020) for four 
doublings before being transitioned to DMEM. All cells were cultured at 37°C in a 
humidified incubator supplied with 5% CO2 and maintained at a low passage 
number (< 20 passages for cancer). Prior to expansion and freezing, a small 
sample of each primary fibroblast was expanded to determine each cell's Hayflick 
limit to ensure that experiments could be performed prior to the onset of 
replicative senescence. A complete list of drugs used in this study is included in 
Table 3.2. 
 
Coculture screen using JC1 dye 
Fibroblast cell lines were grown to 80% confluence before being trypsinized and 
stained with 5 μM CellTrace Violet Proliferation dye (Thermofisher #C34557) in 
PBS at a concentration of 1 × 106 cell/ml for 15 min at 37°C. 1,500 stained cells 
were plated in 40 μl FluoroBrite media (Thermofisher # A1896701), 
supplemented with 10% FBS, 2 mM glutamine, and penicillin/streptomycin, in a 
Greiner clear 384‐well plate (#781986) and allowed to adhere for 3 h. Cancer cell 
lines were then trypsinized and stained with 1.5 μg/ml (final concentration) JC‐1 
(Thermofisher # T3168) in FluoroBrite at a concentration of 1 × 106 cell/ml for 20 
min at 37°C. Cancer cells were then plated at 1,500 cells in 40 μl FluoroBrite per 
well in the 384‐well plate. For monoculture conditions, unlabeled cancer cells 
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were added to each well, in order to keep the cell density consistent with 
coculture conditions. Cells were allowed to adhere overnight. The following 
morning, 8 μl of a 10× drug stock was added to the wells using a VIAFLO 96 
Electronic 96‐channel pipetting robot. JC‐1 fluorescence was then read at five 
spots across each well using a Tecan M1000 Pro Plate Reader at the excitation 
wavelength of 535 nM ± 17 nM and an emission wavelength of 590 nM ± 17 nM 
every 8 h for 72 h. Background fluorescence was determined by treating labeled 
cells with alamethicin, a membrane permeabilizing agent that punctures plasma 
membrane and mitochondrial membranes. Fluorescence measurements were 
normalized relative to pre‐drug treatment values for each well. 
 
Cell viability and cell death assays 
Cell viability assays were performed either using CellTiter‐Glo (cat# G7570), for 
cells grown in monoculture, or flow cytometry, for coculture assays (other than 
the coculture screen, described above). For CellTiter‐Glo, which measures 
viability as a function of ATP concentration, cells were plated in Greiner 96‐well 
plates (cat# 655 090) at 5,000 cells per well in 100 μl of their respective growth 
media and allowed to adhere overnight. 10 μl of a 10× drug stock, diluted in PBS, 
was added to each well. Cells were subsequently allowed to grow at 37°C for 72 
h. At 72 h post‐drug addition, 33 μl of CellTiter‐Glo reagent was added to each 
well. The CellTiter‐Glo assay was performed according to manufacturer's 
directions, with the reagent diluted 1:3 (relative to media volume). Luminescence 
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was read using a Tecan M1000 Pro Plate Reader. Cell death measurements to 
validate the JC‐1 screen data were collected using the Live/Dead Violet reagent 
(Thermofisher cat# L34963) and analyzed by flow cytometry. Cancer cells and 
fibroblast cells were plated at a 1:1 ratio in DMEM and allowed to adhere 
overnight. Drugs were added from a 1,000× stock, and cells were exposed for 
the specified times. Cells were trypsinized at the specified times, suspended in 
PBS at a concentration of 1 × 106 cells/ml and stained with a 1:1,000 dilution of 
the Live/Dead Violet reagent for 30 min on ice. Cells were then fixed with 4% 
formaldehyde for 10 min at room temperature and run on an LSR II FACS 
machine with a laser excitation of 405 nm and emission of 450 nm. 
 
Drug sensitivity of cells grown in 3D culture conditions 
Culturing of TNBC cells in 3D colonies was performed using the “3D on top” 
method developed by Bissell and colleagues88. Briefly, a thick layer of cold 
Matrigel (corning cat#356235) was applied to the bottom of 96 well plates, which 
were subsequently heated to 37°C for 30 min to promote solidification. Cancer 
cells were plated at a concentration of 10,000 cells in 100 μl complete media + 
2% Matrigel and were grown for 72 h to induce 3D colony formation. After 72 h of 
growth, the media were aspirated and media containing drug + 2% Matrigel were 
added to each well. At 72 h post‐drug addition, cell viability was measured by 
adding 100 μl of CellTiter‐Glo reagent to each well. The CellTiter‐Glo assay was 
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performed according to the manufacturer's directions, and luminescence was 
read using a Tecan M1000 Pro Plate Reader. 
 
Growth rate measurements using GFP‐labeled cells 
To determine cell proliferation rate using a fluorescence plate reader, TNBC cells 
were stably transfected with GFP (pRetroQ‐AcGFP1‐N1). Transfected cells were 
selected with puromycin (BT‐20 at 1.5 μg/ml, 468 at 0.5 μg/ml, and 231 at 2 
μg/ml). Cells were selected until a parallel non‐transformed plate exposed to 
puromycin was completely dead. The selected population was subsequently 
sorted by FACS to collect cells with similar levels of GFP fluorescence. For 
coculture experiments, fibroblast cell lines were plated at an 8:1, 4:1, 2:1, 1:1, 
and 1:2 ratio to cancer cells in a Greiner 96‐well plate in 100 μl of FluoroBrite 
media and allowed to adhere for 3 h. Following adherence of fibroblast cells, 
TNBC cells constitutively expressing GFP were plated at a concentration of 
10,000 cells per 100 μl of FluoroBrite media and allowed to adhere overnight. 
Cell measurements were measured every 24 h for 96 h using a Tecan M1000 
Pro Plate reader. 
 
Fluorescence and immunofluorescence microscopy 
For quantitative analysis of p‐H2AX nuclear intensity, fibroblast cells were plated 
at a density of 1,500 cells per 25 μl in DMEM in a 384‐well plate and allowed to 
adhere for 3 h. Cancer cells were stained with 5 μM CellTrace CFSE dye 
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(Thermofisher cat# C34554) at a concentration of 1 × 106 cells/ml in PBS for 15 
min at 37°C. Labeled cells were plated at 1,500 cells per 25 μl DMEM and 
allowed to adhere overnight. Drugs were added from a 10× stock solution in 
PBS, and cells were exposed for 1, 6, and 18 h before being fixed with 4% 
formaldehyde for 10 min at room temperature. Cells were washed twice in PBS, 
then permeabilized with 0.5% Triton X‐100 for 10 min at room temperature. Cells 
were washed twice with PBS; blocked in 10% goat serum (Thermofisher cat# 
16210064) for one hour; stained with the p‐Histone H2A.X (Ser139) antibody 
(Cell Signaling Technologies #9718S) in 1% goat serum in PBS overnight at 4C; 
stained with Alexa‐647 antibody (1:250 dilution, Thermofisher A21244) in 1% 
goat serum in PBS for 2 h at room temperature. Imaging was performed using an 
IXM‐XL high‐throughput automated microscope. Analysis was performed using a 
custom CellProfiler pipeline (available upon request).  
 
SMA analysis by microscopy and FACS 
Fibroblast cells were stained with 1uM CellTracker Deep Red Dye (Thermofisher 
cat#C34565) at a concentration of 1 × 106 cells/ml for 15 min at 37°C and 
subsequently plated in 96‐well plates at a concentration of 10,000 cells per well 
and allowed to adhere for 3 h. Cancer cells were then stained with 5 μM 
CellTrace Violet Proliferation Dye at a concentration of 1 × 106 cells/ml for 15 
min at 37°C and plated at a concentration of 10,000 cells per well and allowed to 
adhere for 24 h. After 24 h, cells were fixed with 4% formaldehyde for 10 min at 
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room temperature and washed twice with PBS. Cells were then permeabilized 
with 0.5% Triton X for 10 min at room temperature, washed twice with PBS, and 
then blocked in 10% goat serum for one hour. Cells were stained with the αSMA 
antibody (1:75 dilution, Cell Signaling Technology cat#19245S) in 1% goat serum 
for 8 hours at room temperature and then stained with the Alexa‐488 antibody 
(1:100 dilution Thermofisher cat#A11008) in 1% goat serum for 1 h at room 
temperature. Imaging was performed using an EVOS FL‐AUTO automated 
fluorescence microscope. A similar process was used for analysis of SMA 
expression by FACS, except following formaldehyde fixation, and cells were 
exposed to 100% methanol for 2 h at −20°C and washed twice with PBS. Cells 
were stained with the αSMA antibody (1:75 dilution, Cell Signaling Technology 
cat#19245S) in 50% Odyssey Blocking Buffer (LI‐COR cat# 927‐40000) 50% 
PBS‐T for 8 hours at room temperature and then stained with the Alexa‐488 
antibody (1:100 dilution Thermofisher cat#A11008) for 1 h at room temperature in 
50% Odyssey Blocking Buffer 50% PBS‐T. FACS was run on an LSR II machine 
with a laser excitation of 488nm and emission of 530 nm. 
 
Mitochondrial priming assay 
Mitochondrial priming assays were performed according to a previously 
published iBH3 protocol89. For monoculture conditions, 1 × 106 cancer cells were 
plated in a 10‐cm dish and allowed to adhere overnight. For coculture conditions, 
fibroblasts were stained with Cell Trace Violet plated at a 1:1 ratio with cancer 
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cells. Twenty‐four hours post‐plating cells were trypsinized and arrayed in a 384‐
well plate. A dose series of BIM peptide (GenScript) was added (100, 33, 10, 3.3, 
1, 0.33 μM) along with either DMSO (vehicle control) or alamethicin (Enzo, BML‐
A150‐0005), a mitochondrial depolarizing agent, which was used at a final 
concentration of 25 μM as a positive control. Plasma membrane permeabilization 
was achieved by the addition of digitonin at a final concentration of 20 μg/ml. 
Cells were incubated with BIM peptide at room temperature for 1 hour before 
being fixed and stained for cytochrome c retention (Fisher cat# BDB560263). 
Samples were analyzed on an LSRII flow cytometer. 
 
Data analysis and statistics 
All statistical analyses were performed using GraphPad Prism and/or MATLAB, 
generally using pre‐built functions (Fisher's exact test, t‐test, etc.). PCA was 
performed using SIMCA, and data were z‐scored (mean centered and unit 
variance scaled). Hierarchical clustering was performed using Spotfire using the 
default settings (UPGMA clustering method; Euclidean distance measure; 
average value ordering weight; z‐score calculation normalization method; empty 
value replacement: NA). Analysis of flow cytometry data was performed using 
FlowJo. Combination Index (CI) was calculated by dividing observed drug 
sensitivity by the expected drug response given Bliss Independence (for two 
drugs, A and B, expected = A + B − [A*B]). 
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Data Availability: 
The complete coculture screening data can be viewed at DOI 
10.15252/msb.20188322 as Table EV3. The CellProfiler scripts used for the 
analyses shown in Figs 3.14, and 3.15 can be viewed at DOI 
10.15252/msb.20188322 Code EV2, and Code EV3, respectively. 
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CHAPTER IV: Fibroblast secretion of IL-8 sensitizes TNBC cells to DNA 
damage independent of altering apoptotic priming. 
 
Abstract: 
 Fibroblasts secrete cytokines, chemokines, and growth factors into the 
tumor microenvironment that promote tumor growth and drug resistance. Pro-
inflammatory cytokines activate pro-proliferative and survival signaling networks 
that aid in preventing the onset of apoptotic cell death in cancer cells.  However, 
it remains unclear if fibroblast secreted factors are able to modulate dug 
response by altering the priming state of cancer cells. Here, I demonstrated that 
conditioned media (CM) collected from fibroblasts is capable of sensitizing or 
desensitizing TNBC cells to DNA damaging chemotherapeutics. I identified the 
pro-inflammatory cytokine IL-8 as being sufficient in inducing the sensitizing 
phenotype. However, I continued to observe an attenuated sensitization 
phenotype using IL-8 depleted CM, suggesting that other soluble factors 
contribute to drug sensitization. Interestingly, the mechanism behind IL-8 
mediated drug sensitization is independent of the apoptotic priming mechanism 
observed in the co-culture screen from chapter 3. Treatment of TNBC cells with 
recombinant IL-8 protein showed no change in the apoptotic threshold of the 
cells. This study demonstrates the ability of fibroblasts to mediate cancer cell 
drug sensitivity through the secretion of soluble factors as well as highlights that 
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there are distinct mechanisms that fibroblasts utilize to sensitize TNBC cells to 
DNA damage.  
 
Introduction: 
 As highlighted in chapter 3, my co-culture screening approach identified 
novel cancer:fibroblast interactions that alter drug sensitivity through modulating 
apoptotic priming. However, the molecular mechanisms underlying the change in 
the apoptotic threshold of cancer cells was not defined, necessitating a deeper 
characterization of the cancer:fibroblast signaling interactions to better 
understand the sensitizing phenotype. Interactions between fibroblasts and 
cancer cells can be mediated through a variety of methods, such as the secretion 
of soluble factors (e.g. growth factors, cytokines, etc.), the deposition of matrix 
proteins, and/or direct cell-cell contact. Given the broad range of molecules 
involved in each of these different modes of interaction, it is necessary to limit the 
investigation to one type of cancer:fibroblast interaction.  
Fibroblasts are responsible for the secretion of a myriad number of 
cytokines, chemokines, and growth factors in the tumor microenvironment. 
Fibroblast mediated secretion of pro-inflammatory cytokines promotes tumor cell 
proliferation and survival through multiple signaling axes, such as IL-6 mediated 
JAK/STAT3 activation as well as the activation of NF-kB90–93. Secretion of growth 
factors by fibroblasts, such as HGF, also contribute to cancer cell proliferation as 
well as mediating drug desensitization to targeted chemotherapeutics49. 
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However, the ability of soluble factors to alter the apoptotic threshold of cancer 
cells has not been characterized. Therefore, I chose to focus on testing the ability 
of soluble factors to mediate the apoptotic priming dependent drug sensitizing 
phenotype seen in the C12385, HUF, and WS1 cancer:fibroblast interactions.  
 
Results: 
 To investigate the molecular mechanisms that dictate the drug sensitizing 
and desensitizing phenotypes observed in co-culture of TNBC cells and 
fibroblasts, I tested whether conditioned media (CM) from fibroblast cells 
modulates drug response. To measure the rate of death as well as the lethal 
fraction of TNBC cells, I adapted a fluorescent based assay that utilizes the dye 
sytox green (Fig 4.1A). Sytox green is a cell impermeable dye that fluoresces 
only when bound to DNA. As cells die, their membrane structure is disrupted 
which allows sytox green to enter the nucleus and bind to DNA. Conditioned 
media was collected following 48 hours of culture with fibroblasts and added to 
TNBC cells prior to addition of sytox green and teniposide, a topoisomerase 
inhibitor. Sytox green fluorescence was measured at 12-hour time points as a 
proxy for cell death. At the end of the time course, triton-x (0.02% final 
concentration) was added to each well to permeabilize the membranes of any 
sytox green excluding viable cells. Each well was read again, with 100% of the 
cells now sytox green positive, and the resulting fluorescence measurement was 
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used as a proxy for the total number of cells in a well. These pre and post-
permeabilization measurements were used to calculate the lethal fraction of each 
condition.  
The lethal fraction of each CM condition was compared to the lethal 
fraction of control cells and then Z-scored for each cell line. A positive Z-score, 
displayed as red and seen in the Hs27A and Hs5 conditions, indicates a CM 
mediated drug desensitization to teniposide. A negative Z-score, displayed as 
blue and seen in the C12385, HUF, and WS1 conditions, indicates a CM 
mediated drug sensitization to teniposide. To determine if CM was altering other 
features of death besides the lethal fraction, such as onset time or rate, I focused 
on collecting kinetic death measurements of three strong sensitizing 
cancer:fibroblast interactions. These interactions included the two uterine 
fibroblasts C12385 and HUF as well as the skin fibroblast WS1. I found that 
conditioned media from WS1, HUF, and C12385 increased the rate of death in all 
six TNBC cell lines, compared to control cells, in response to teniposide 
treatment (Fig 4.1C). In contrast, conditioned media from Hs27A, a bone 
fibroblast cell that caused a desensitizing phenotype, generally did not alter 
TNBC drug response, although these data were variable across the six TNBC 
cell lines (Fig 4.1B and C). These data indicate that secreted factors from tissue 
specific fibroblasts are sufficient to sensitize TNBC cells to DNA damage.  
To identify secreted factors that are responsible for these phenotypes, I 
profiled conditioned media obtained from sensitizing and desensitizing fibroblasts 
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for the presence of 45 common cytokines, chemokines, and growth factors (Fig 
4.2A). To identify factors that are involved in drug sensitization, I plotted the 
relative protein levels of each factor against the relative survival ratio calculated 
from the co-culture screen in chapter 3 and calculated the correlation. A negative 
correlation between these two values would reveal potential hits, since 
sensitizing environments produce a low relative survival ratio and factors that 
control the sensitizing phenotype would be expected to be expressed at relatively 
high levels. Conversely, a positive correlation would indicate hits involved in drug 
desensitization, since the relative survival ratio will be high as well as the relative 
protein level of the factor. Of the 45 cytokines profiled, I observed a strong 
negative correlation for IL8 (Fig 4.2 B and C). I also observed a positive 
correlation between relative drug sensitivity and secretion of IL6, a cytokine that 
is already known to induce resistance to DNA damaging chemotherapies (Fig 
4.2C)90,94.  
To test if IL8 was sufficient to alter sensitivity to DNA damage, I treated 
BT20 cells with recombinant IL8 and measured the rate of death in response to 
camptothecin, a topoisomerase inhibitor. Addition of IL8 increased the rate of 
DNA damage induced cell death by approximately 2.5-fold, whereas cells treated 
with recombinant IL6 decreased the rate of cell death by approximately 2-fold 
(Fig 4.2D). To further determine the role of IL8 in conditioned media induced drug 
sensitization, I treated conditioned media obtained from WS1, HUF, or C12385 
fibroblasts with an IL8 neutralizing antibody. In all three conditions, IL8 
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neutralizing antibodies inhibited the drug sensitization phenotype induced by 
conditioned media (Fig 4.2E). Interestingly, the use of IL8 neutralizing antibodies 
failed to restore BT20 drug response to the level of control cells (Fig 4.2 E black 
line), arguing for the fact that other secreted factors in conditioned media also 
contribute to the drug sensitization phenotype. Thus, cytokine analysis of CM 
derived from sensitizing fibroblasts identified and demonstrated that the pro-
inflammatory cytokine IL-8 plays an important role in sensitizing TNBC cells to 
DNA damage. 
To test if IL8 is mediating drug sensitivity in cancer cells by altering the 
apoptotic threshold, I utilized the iBH3 assay to measure the priming state of 
cancer cells exposed to recombinant IL8 protein. In brief, cancer cells are treated 
with digitonin to permeabilize the cell membrane and exposed to increasing 
concentrations of recombinant BIM peptide before measuring the amount of 
cytochrome c protein retained in the mitochondria by FACS. Cells that are more 
primed for death will undergo MOMP at a lower BIM concentration and lose most 
of their mitochondrial cytochrome c protein. Cells treated with DMSO but no BIM 
protein or the mitochondrial pore forming agent alamethecin serve as negative 
and positive controls (Fig 4.2F). BT20 cells were exposure to IL8 for increasing 
amounts of time before apoptotic priming was tested. However, there was no 
observable difference in the BIM dose response curves or EC50 values between 
control cells and cells exposed to IL8 protein (Fig 4.2G). These data argue that 
IL8 is not acting to alter drug response through modulating apoptotic priming and 
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that other interactions are responsible for the priming mediated sensitizing 
phenotype observed in the co-culture screen performed in chapter 3.  
 
Discussion: 
 In this chapter I explored a possible mechanism underlying the change in 
apoptotic priming observed in the sensitizing and desensitizing phenotypes 
previous characterized in the co-culture screen from chapter 3. I demonstrated 
the ability of conditioned media obtained from fibroblasts cells to alter the drug 
sensitivity of TNBC cells. Specifically, I showed C12385, HUF and WS1 
conditioned media sensitized TNBC cells to DNA damage while Hs27A 
conditioned media desensitized cells to damage. It is interesting to note that 
although the general trend in altered drug sensitivity was consistent whether 
lethal fraction or the rate of death was measured, there was a moderate amount 
of variability in the phenotype depending on which measurement was used. For 
instance, measuring lethal fraction of cancer cells treated with Hs27A conditioned 
media showed a strong desensitizing phenotype but there was little change in the 
rate of death compared to control cells. Similarly, there was a more variable 
response in the drug sensitivity phenotype when measuring lethal fraction of 
C12385, HUF, and WS1 treated cells compared to the observed universal 
increase in the rate of cell death. These disparities highlight the complexity of 
measuring cell death related phenotypes and the need to validate the data using 
multiple assays.  
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 To further elucidate the factors responsible for the conditioned media 
sensitizing phenotype, I used Luminex cytokine analysis to identify proteins 
whose levels were anti-correlated to viability measurements. I identified the 
inflammatory cytokine IL8 as a mediator of drug sensitivity in TNBC cells. 
Previous research has revealed that IL8 modulates cell death, however the 
studies have demonstrated IL8 as having both a positive and negative effect95–97. 
I found that IL8 increased the rate of death in TNBC cells independent of 
changing apoptotic priming. IL8 signals through the CXCR1/2 receptors which 
control the activation of many downstream effector molecules, including NF-KB. 
The timing and dynamics of these signaling axes can lead to either pro-survival 
or pro-death outcomes in the cell98. As indicated by the data presented in this 
chapter as well as the previous studies detailing the pro-survival roles of IL8 in 
cancer cells, there needs to be a more comprehensive understanding of the 
crosstalk between inflammatory and apoptotic signaling networks. Deeper 
analysis will clarify the molecular mechanisms that modulate the context 
dependent pro-survival vs pro-apoptotic phenotypes associated with IL8 
signaling.  
 It should also be noted that while I identified IL8 as a mediator of drug 
sensitivity, I only screened a small portion of known cytokines, chemokines and 
growth factors. The fact that neutralizing IL8 signaling using antibodies still 
shows an increase in the rate of cell death as well as IL8 not altering the 
apoptotic threshold of cancer cell indicates that there are other interactions that 
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contribute to the observed phenotypes. A more detailed analysis of the 
composition of fibroblast conditioned media as well as the investigation of the 
effect of simultaneous exposure to multiple cytokines on drug sensitivity will yield 
valuable information in the underlying molecular mechanisms and signaling 
pathways responsible for the drug sensitization phenotype.   
 
Materials and Methods: 
 
Conditioned media assays 
Fibroblasts were plated in a 10 cm dish at a concentration of 750,000 cells 
in 10mL of DMEM and allowed to adhere. Cultures were incubated at 37C for 48 
hours and conditioned media was collected and filtered through a 0.45um syringe 
filter. To test whether conditioned media altered drug sensitivity, cancer cell lines 
were plated in the respective conditioned media at a concentration of 3000 cells 
per 50uL conditioned media in a 384 well plate and allowed to adhere overnight. 
24 hours post plating, 5uL of a 10x drug stock was added to each well along with 
the Sytox green reagent (Fisher Scientific, S7020). Sytox Green was used at a 
5uM final concentration, and fluorescence was measured using a Tecan Plate 
reader. The Sytox Green fluorescence reading is proportional to the number of 
dead cells in the well. To determine numbers of live cells and the percent 
viability, Triton x100 was added to each well (0.2% for 3 hours at 37C) to induce 
permeabilization of remaining live cells.  
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Cytokine analysis 
Conditioned media for the selected fibroblast lines were collected 48 hours 
post plating and arrayed in biological replicates with two technical replicates 
each. Cytokine and chemokine analysis was performed according to the 
manufacturer’s instructions for the Cytokine/Chemokine/Growth Factor 45-Plex 
Human ProcartaPlex™ Panel 1 kit obtained from Thermofisher (cat# EPXR450-
12171-901). 
 
Mitochondrial priming assay 
Mitochondrial priming assays were performed according to the iBH3 
protocol from Ryan et al89. For priming, 1x10^6 cancer cells were plated in a 
10cm dish and allowed to adhere overnight. Recombinant IL-8 cytokine was 
added for the specified time and cells were then trypsinized and arrayed in a 96 
well plate. A dose series of BIM peptide was added (100uM, 33uM, 10uM, 
3.3uM, 1uM, 0.33uM) along with either DMSO (vehicle control) or alamethicin, a 
mitochondrial depolarizing agent, which was used at a final concentration of 
25uM as a positive control. Plasma membrane permeabilization was achieved by 
the addition of digitonin at a final concentration of 20 µg/mL. Cells were 
incubated with BIM peptide at room temperature for 1 hour before being fixed 
and stained for cytochrome c retention (Fisher cat# BDB560263). Samples were 
analyzed on an LSRII flow cytometer. 
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CHAPTER V: DISCUSSION 
 
An ongoing challenge in the treatment of cancer is choosing the optimal 
drug or drug combination for a particular patient. Drug efficacy varies 
substantially between patients, even within a single cancer subtype, which 
necessitates a better understanding of the factors that alter cancer drug 
sensitivity. Several studies have investigated the link between cancer genetics 
and drug response, which accounts for a fraction of the observed variability, but 
even with comprehensive genomic information, predicting therapeutic responses 
tends to be beyond our current grasp. One limitation is the dearth in 
understanding how non-genetic variations alter drug response. Components from 
the tumor microenvironment, for example CAFs, have been shown to influence 
the drug sensitivity of cancer cells. However, we currently lack the knowledge 
necessary to predict which fibroblast-cancer-drug interactions will alter drug 
sensitivity or the directionality of the response. A deeper understanding of the 
factors that govern tumor-stroma interactions will reveal potential biomarkers or 
“rules” that would function to increase our ability to predict therapeutic responses 
in a variety of environmental contexts. 
In my thesis, I use an optimized high throughput screening method to 
investigate how cancer-fibroblast interactions mediate response to DNA 
damaging chemotherapeutics. I focused primarily on solid epithelial tumors, 
including those in the “triple-negative” breast cancer class, and non-small cell 
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lung cancer class. I demonstrated the ability of a JC-1 dye-based assay to 
accurately measure cell death in an in vitro co-culture system and performed a 
screen to determine the effect of 4,032 drug-cancer-fibroblast interactions on 
cancer cell drug sensitivity. Analysis of the screen data showed that a bulk of the 
interactions observed had minimal effect on drug sensitivity, however, a small 
subset of interactions either greatly sensitized or desensitized cancer cells to 
DNA damaging agents. PCA of the data also revealed that co-culture of cancer 
cells with fibroblasts was sufficient to capture the clinically observed difference in 
basal drug response between two TNBC sub-classes, Basal-Like (BL) and 
Mesenchymal-Like (ML). 
My study revealed two interesting patterns: 1) For an individual cancer-
fibroblast interaction, the change in drug sensitivity was generally independent of 
which drug was tested, and 2) For an individual cancer-drug interaction, the 
direction of the effect was specific to the tissue that the fibroblast was obtained 
from. I further demonstrated that the drug independent sensitivity effect was 
caused by a change in apoptotic priming induced by cancer-fibroblast 
interactions. Using this knowledge, I was able to predict the efficacy of a 
combination therapy consisting of a DNA damaging agent and a pan-BCL-2 
inhibitor based on the environmental context. 
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Matching your research question with the right cell death assay. 
 Measuring cell death and proliferation is a complex process, with multiple 
assays available that yield different types of information. Throughout my thesis I 
used four different assays to measure cell death and proliferation. The assays 
are split into two main categories, assays that can be used to measure death and 
proliferation in one population in mono-culture or assays that can be used to 
measure death and proliferation in one population in both mono and co-culture 
(an overview of each assay can be viewed in Table 5.1). 
 
 CellTiter Glo Sytox Green 
GFP 
Fluorescence 
JC-1 Dye 
Culture 
Conditions 
Mono-culture Mono-culture 
Mono-culture 
or 
Co-culture 
Mono-culture 
or 
Co-culture 
Cost $$$ $$ $$ $ 
Throughput 
High 
(add to plate 
then measure) 
High 
(add to plate 
with drug) 
Low 
(need to make 
each cell line) 
High 
(20 min to 
stain then 
plate) 
Instrument 
Used 
Plate Reader Plate Reader 
Plate Reader 
or 
Microscopy 
Plate Reader 
Measures 
(Using a plate 
reader) 
Proliferation 
Cell Death 
Proliferation 
Cell Death 
Proliferation Cell Death 
Kinetics 
Yes 
(need multiple 
plates) 
Yes Yes Yes 
 
Table 5.1: Comparison of cell death assays. A detailed comparison of the four 
cell death assays that were used in the thesis.  
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The first mono-culture only assay is CellTiter Glo, which works by lysing 
the cells in each well and measuring the total ATP as a marker of viable cells. 
CellTiter Glo is very accurate and sensitive, having a detection limit of 10 cells, 
but is quite expensive. CellTiter Glo can be used to measure either cell death or 
proliferation by comparing the number of viable cells in a treated well compared 
to a control well. To measure the kinetics of death or proliferation, however, a 
separate plate must be used for each timepoint since the cells are lysed as part 
of the measurement. This process can introduce noise into the experiment as the 
kinetic measurements consist of multiple separate wells instead of following one 
well through time. Also, throughput is limited due to the base cost of CellTiter Glo 
and the need for multiple plates for kinetic measurements. This assay is best 
suited for observing cell death at a single timepoint. In my thesis I used this 
assay to measure dose curves of cancer cell lines grown in mono-culture treated 
with drug for 72 hours either in 2D or 3D culturing conditions.  
The second mono-culture only assay is the use of the Sytox Green dye, 
which works by entering dead cells with disrupted cell membranes and binding to 
DNA. When bound to DNA, Sytox Green produces a fluorescent signal which can 
then be read by a plate reader to determine the number of dead cells present in 
the well. Sytox Green is quite accurate and moderately priced. Sytox Green can 
be used to measure the kinetics of cell death by reporting the number of dead 
cells in the well over time. Sytox Green can also be used to measure cell 
proliferation and lethal fraction at a single timepoint by first measuring the 
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number of dead cells in a well, then adding an agent to kill the remaining viable 
cells, and then measuring the total number of cells in the well to calculated the 
number of viable cell that were in the well. Due to the ease of use, adding the 
Sytox dye to the well at the beginning of the experiment, throughput is quite high. 
This assay is best suited for observing cell death over a range of timepoints as 
well as measuring the lethal fraction at a single timepoint. In my thesis I used this 
assay to measure the rate of death or lethal fraction of cancer cells treated with 
media conditioned by fibroblast cells.  
The first assay that works in either mono-culture or co-culture is 
measuring GFP fluorescence. This assay works by integrating a cassette coding 
a soluble cytoplasmic GFP molecule controlled by a constitutive promoter into a 
cancer cell line. Each transfected cell line is then selected for the cassette using 
puromycin and sorted by FACS to select for a population that of cells with similar 
GFP fluorescence. Cytoplasmic GFP fluorescence scales with cell number and 
can be used to determine the number of viable cells in a well. Since only one 
population of cells are labeled, this assay can be used to measure death and 
proliferation of one population when cultured with other cell types. The GFP 
fluorescence assay is accurate and moderately priced, given the time and 
reagents needed to create each cell line. GFP fluorescence can be used to 
measure cell death or proliferation using automated microscopy but only cell 
proliferation using a plate reader. The reason behind this is that when a cell dies 
the cytoplasmic GFP molecules form small long-lasting bright puncta that are 
103 
 
seen by a plate reader and inflate the total well fluorescence, i.e. the number of 
viable cells. These same puncta are observed when using automated 
microscopy but are filtered out using a size threshold in CellProfiler when 
determining the number of viable cells, allowing for the calculation of cell death. 
The throughput of this assay is limited by the need to create each cell line as well 
as the use of automated microscopy to measure cell death. Therefore, this assay 
is best suited for measuring the effect of drugs on cell proliferation using a plate 
reader. In my thesis I used this assay to determine the effect of co-culture with 
fibroblasts on cancer cell proliferation with and without the addition of targeted 
growth factor inhibitors.  
The second assay that works in either mono-culture or co-culture is the 
JC-1 dye, which works by staining healthy mitochondria in viable cells with red 
fluorescent puncta. When the cell begins to die, healthy mitochondria are subject 
to mitochondrial outer membrane permeabilization (MOMP) and lose the red 
fluorescent puncta which can be observed using a plate reader. Since only one 
population of cells are labeled with the JC-1 dye, this assay can be used to 
measure death of one specific population when cultured with other cell types. 
The JC-1 dye is inexpensive and accurate in measuring cell death, although 
there is a relatively high basal background signal. The JC-1 assay can measure 
cell death kinetics in a single well over time but cannot measure cell proliferation. 
The throughput of this assay is quite high as the cells only need to be stained for 
20 minutes before being plated and they can be measured using a plate reader. 
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Therefore, this assay is best suited for co-culture experiments involving multiple 
cell lines. In my thesis I used this assay to measure death in a large co-culture 
screen between TNBC cell lines and fibroblast cells.  
In terms of predicting patient outcomes, the information obtained from the 
JC-1 assay would be the most informative. The JC-1 assay is the only assay I 
used that can measure the cell death specifically of the cancer cell population 
when co-cultured with fibroblasts. Since this co-culture condition is the closest to 
mimicking an in vivo environment, the measurements observed from the JC-1 
assay would hold the most weight in predicting drug efficacy in patients. The 
kinetic measurements of death obtained from the JC-1 assay could be used in 
determining a viable patient dosing strategy while the terminal viability 
measurement at 72 hours would inform clinicians which drugs would be the most 
efficacious in treating the patient’s tumor. 
 
Cancer:fibroblast interactions in vitro are sufficient to replicate clinically 
observed differences in drug sensitivity between subclasses of TNBC cells. 
 Studying cancer in vitro using cell lines derived from patient tumors has 
revealed a tremendous amount of information about cancer cell biology, including 
how cancers induce cell death in response to DNA damage. Yet, there has been 
a persisting criticism of in vitro studies concerning how the environment is 
artificial and does not mimic the interactions the tumor is seeing in an actual 
cancer patient. Therefore, the gold standard for validating phenotypes in the field 
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of cancer biology has traditionally been to test the phenotype in vivo using an 
animal model. While in vivo animal models provide an environment that more 
closely mimics the physical and spatial cancer physiology observed in patients, in 
vivo systems introduce a range of complicating factors. The diversity of cell types 
creates a complex network of interactions between the cancer cells and the 
surrounding environment. This multi-faceted complexity reduces the ability to 
study the effect of individual interactions on cancer cell behavior. However, I 
demonstrated that an in vitro co-culture system can identify tumor-environment 
interactions that underlie a drug sensitivity phenotype observed in vivo.  
 Triple-Negative Breast Cancers are breast cancers that are characterized 
by the lack of the estrogen receptor (ER), progesterone receptor (PR), and 
amplifications in the HER2 receptor. TNBCs are divided into multiple subclasses, 
with the BL and ML subclasses being observed to have very different drug 
sensitivities clinically in patients. The BL subclass is more sensitive to DNA 
damaging chemotherapeutics, while the ML subclass is more resistant. However, 
when this feature is tested in vitro using a basic culturing system, I observe no 
statically significant difference in drug sensitivity between the two classes. These 
data argue that the subclass specific drug sensitivity phenotype is controlled by 
some characteristic intrinsic to in vivo physiology, which is lacking from in vitro 
systems (Fig 3.1A-C). 3D culturing of cancer cell lines in Matrigel better 
recapitulates in vivo morphologies while still offering the throughput of traditional 
in vitro systems. I tested the ability of 3D culture to induce the differential drug 
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response between the TNBC sub-classes and, while I observed a general 
desensitization to DNA damaging chemotherapeutics, I was not able to recover 
the sensitivity phenotype (Fig. 3.1D and 3.2D). However, when I performed PCA 
on my data set of drug responses from specific cancer-fibroblast-drug conditions 
measured using an in vitro co-culture system I was able to recapitulate the in vivo 
drug sensitivity phenotype (Fig 3.10A and F). This result demonstrates the ability 
of in vitro work to identify specific interactions in the in vivo environment that are 
responsible for altering drug sensitivity without the need to use animal models.  
Being able to use in vitro generated data to understand in vivo biology, 
would allow for the characterization of important interactions using cheaper, 
higher throughput, and more flexible methods. Expanding on this concept, it 
would be possible to screen a variety of cell types, matrix proteins, and soluble 
factors to identify specific interactions that also recapitulate the BL vs ML drug 
sensitivity difference. Using this data, it may be possible to model the behaviors 
of cancer cells in a complex in vivo environment using only measurements 
collected in simpler in vitro environments. This approach would allow for the 
selection of the most promising combination therapies and in the end save on 
animal handling costs and time. One caveat is that generating complex models 
using co-culture based interactions would require relatively limited “higher order” 
interactions. Testing other environmental components, and the degree to which 
higher order influences exist, are important future efforts based on our work. 
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Fibroblast mediated alterations in drug sensitivity are diverse in not just 
the magnitude of the response but also the directionality.  
 The tumor microenvironment plays a diverse role in supporting cancer 
growth, survival, progression, and drug response. The most abundant non-
malignant cell in the environment are CAFs, normal fibroblasts that have been 
reprogrammed to myofibroblast-like expression state. CAFs function to deposit 
and degrade matrix, secrete growth factors, cytokines, and chemokines, as well 
as mediate cell-cell signaling through integrin interactions. Several studies have 
begun to explore the complex relationship between CAFs and cancer cell drug 
response and reported that interactions with CAFs generally desensitize cancer 
cells to chemotherapeutics with rare instances of drug sensitization. This drug 
desensitization phenotype is thought to occur regardless of the origin of the CAF, 
as shown by Kornelia Polyak and colleagues who observed lapatinib resistance 
in both mammary and brain derived normal fibroblasts and CAFs29. Given these 
previously reported phenotypes, it was surprising to observe that the screening 
data produced using the JC-1 co-culture system revealed striking bidirectional 
effects on drug response. Interestingly I also observed an almost equal 
distribution between statistically significant desensitizing, 2296, and sensitizing, 
1688, interactions (Fig 3.3E and Table 3.4). The magnitude of the responses also 
varied greatly, with some sensitizing and desensitizing interactions inducing a 
two-fold increase or decrease in cell viability (Fig 3.3E).  
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I hypothesize that I was able to find these sensitizing interactions because 
of the screen design and methodology used. As I demonstrated in chapter 2, the 
GFP based assay that was used previously to measure these interactions was 
only sensitive in capturing proliferation and not cell death. Desensitizing drug 
interactions would be captured as the assay was adept at capturing increased 
GFP fluorescence, however the stability of GFP complicates the capture of 
sensitizing interactions that rely on a decreasing signal. The JC-1 based assay is 
insensitive to protein degradation and therefore able to capture both types of 
interactions without sacrificing assay throughput. Moving forward, there needs to 
be a greater effort to be cognizant of precisely what the assay is measuring, 
especially when measuring cell death. Scott Dixon and colleagues have recently 
as highlighted this fact with the development of the STACK assay that measures 
single cell death kinetics in a population using high throughput fluorescence 
microscopy99. It is also important to note that the assay used did not sacrifice 
throughput for sensitivity, as only around 2% of interactions screened showed a 
statistically significant sensitizing or desensitizing phenotype. The rarity of these 
interactions requires that the screening space must be large in order to identify 
hits. Future use of the screening methodology designed and optimized in this 
study will lead to identification of novel cancer-fibroblast interactions and a 
deeper understanding of the tumor microenvironment.  
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Fibroblasts derived from metastatic and non-metastatic tissues correlate with the 
desensitizing and sensitizing phenotypes. 
 One of the aims of this thesis was to explore the relationship between the 
fibroblasts derived from metastatic sites of TNBCs versus non-metastatic sites. 
The data presented in this thesis demonstrates that there is a divergent effect on 
TNBC chemosensitivity based on the tissue that the fibroblast was derived from. 
Fibroblasts derived from common metastatic tissues, such as brain or lung, 
desensitized TNBC cells to targeted therapies as well as DNA damaging agents. 
I also found that these fibroblasts desensitized the more aggressive 
mesenchymal subtype of TNBC to a greater degree than the less aggressive 
basal-like subtype. This observation could explain why TNBC tumors that are 
able to metastasize, the mesenchymal subtype, become chemo-resistant after 
establishing a tumor at one of the four common metastatic tissues. Further study 
into the connection between the gene expression state of the mesenchymal 
subtype of TNBC and the secretory pattern of the fibroblasts derived from 
metastatic sites would aid in the development of better cancer therapies. 
Combination therapies would be used to block the interactions between the 
TNBC cells and fibroblasts which would then sensitize the cancer cells to 
approved chemotherapies and improve patient outcomes.  
 Another discovery I presented in my thesis was that fibroblasts derived 
from uncommon metastatic sites, particularly the skin and uterus, had a 
sensitizing effect on TNBC cells exposed to drugs. This was surprising since it 
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has been noted in the literature that fibroblasts generally have a desensitizing 
effect on cancer cells regardless of their origin. This data could help explain how 
the metastatic pattern of TNBC has been limited to four tissues since the advent 
of neoadjuvant chemotherapy, which is used to shrink primary tumors before 
surgery. Micro-metastases that have migrated to uncommon tissues would be 
sensitized to the neoadjuvant chemotherapeutic treatment and be killed before 
growing into metastatic tumors. Further understanding how the fibroblasts 
derived from non-metastatic tissues sensitize TNBC cells to drugs would improve 
combination therapies. Using a drug that mimics these interactions for tumors 
that have migrated to metastatic tissues would increase the effectiveness of DNA 
damaging agents and improve patient outcomes. 
 
Are TNBC preferentially enriched for sensitizing interactions? 
One caveat to the observed enrichment in sensitizing interactions is that I 
only screened cancer:fibroblast interactions using one cancer type. It is possible 
that the triple-negative class of breast cancer is preferentially enriched for these 
interactions compared to ER/PR or HER2 amplified breast cancers, or other 
types of cancer in general. Therefore, it would be advisable to expand the 
screening approach first to other breast cancer cell lines and finally to other 
cancer types. Expanding the cancer types screened would provide answers to 
two interesting questions: 1) Is the ratio of sensitizing to desensitizing 
interactions consistent among cancer types? and 2) Does the identity of the 
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fibroblasts the mediate these phenotypes change based on the cancer type 
being screened? Identification of sensitizing interactions that span multiple 
cancer cell types would increase the therapeutic options facing those patients as 
well as increasing the efficacy of already used DNA damaging agents.     
 
Do the sensitizing and desensitizing phenotypes validate in vivo? 
As previously mentioned, the gold standard for validating a cancer related 
phenotype is to test it using an in vivo animal model. Drug response could be 
measured in animals receiving a co-injection of luciferase expressing cancer 
cells and either sensitizing or desensitizing fibroblasts into the mammary fat pad. 
The injection methodology would have to be optimized to increase fibroblast 
seeding at the site of tumor initiation, as our data suggest that Matrigel should 
not be used, due to competition between Matrigel and fibroblast mediated 
interactions. Specifically, I observed that drug desensitization mediated by 
culture in Matrigel is dominant over the cancer-fibroblast co-culture sensitizing 
phenotype (Fig 3.16). Replicating the phenotypes in vivo would also test how 
robust the CAF mediated drug response phenotype is. The co-culture system 
where I observed the large sensitization and desensitization phenotypes, up to a 
2-fold change from control cells, confined the two cell types to a small area and 
forced cell-cell interactions. However, injection of the cells in an animal model 
would allow for more movement and introduce other cell-cell interactions besides 
the CAF-tumor interaction in the co-culture system. If the phenotype is robust, 
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the introduction of other cell-cell interaction would not change the CAF mediated 
alteration of drug response. I would also be able to measure the dominance of 
the novel sensitizing interactions I discovered. Murine mammary fibroblasts, 
which have been previously shown to desensitize breast cancer to 
chemotherapeutics, would infiltrate the tumor and compete with the sensitizing 
CAFS to modulate cancer cell drug sensitivity39. Determining the dominance of 
the sensitizing phenotype would be important for its use as a therapy and aid in 
predicting what environments it can be used in. 
 
Exploring beyond fibroblasts, adding immune cells to the environment. 
 The work presented in my thesis has shown that interactions between 
fibroblasts and cancer cells change drug response, but the in vivo tumor 
microenvironment is composed of many more elements than just fibroblasts. To 
further model how environmental interactions influence cancer cell 
chemosensitivity, the next step would be to add another component of the 
environment to the in vitro co-culture system and test if the observed sensitizing 
or desensitizing phenotypes are altered. The next component of the 
microenvironment that I would like to add would be immune cells. The tumor 
microenvironment is highly inflammatory and attracts many types of immune cells 
such as lymphocytes, macrophages and dendritic cells. One subset of immune 
cells that I would be interested in testing would be T-cells. T-cells are recruited to 
the inflammatory microenvironment and, once activated, target cancer cells and 
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induce death. I would like to add activated T-cells to a select number of drug-
fibro-cancer combinations and measure whether the basal rate of death of the 
cancer-fibroblast combination is altered using the JC-1 assay. I hypothesize that 
the secretory pattern of fibroblasts derived from common metastatic tissues 
would reduce the effectiveness of activated T-cells resulting in the conserved 
desensitization to chemotherapeutics. 
 
Diving into the data, directions for future research. 
 The screen performed in my thesis to investigate the effect of cancer-
fibroblast interactions on the efficacy of chemotherapeutics yielded a large 
amount of data. In my thesis I performed PCA to determine large scale trends in 
the data across the six cancer cell lines, which resulted in the described 
difference between fibroblasts derived from metastatic versus non-metastatic 
sites. However, further analysis of the data can reveal other research questions 
that would aid in understanding interactions that alter cancer cell response to 
chemotherapeutics.  
 My thesis focused on fibroblast specific interactions, however preliminary 
analysis of the data also reveals drug specific and fibroblast independent 
interactions that alter therapeutic response. For example, the efficacy of 
microtubule poisons is decreased when cancer cells are co-cultured with 
fibroblasts regardless of the anatomical location they were derived from. RNAseq 
analysis comparing the changes in expression state between cancer cells in 
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mono-culture versus co-culture across the 16 fibroblast lines for one cancer cell 
line would elucidate the molecular mechanism behind the resistant phenotype. 
Understanding the underlying mechanism would allow for the development of 
combination therapies to increase the effectiveness of microtubule poisons.  
 Another facet of the data that can be further explored are the divergent 
sensitivity phenotypes observed between fibroblasts derived from the same 
anatomical area. For example, there were two liver derived fibroblasts that had 
opposite drug independent sensitivity phenotypes. Comparing the expression 
profiles and secreted proteins between these two fibroblasts would reveal 
valuable insights into the molecular mechanisms underlying the change in 
apoptotic priming observed in cancer cells when co-cultured with these 
fibroblasts. 
 
CAFs alter cancer cell drug response by modulating apoptotic 
priming. 
 When a cell is exposed to a drug, commitment to cell death is a function of 
two properties. First, the degree to which the apoptotic signaling pathway is 
activated and second, the basal priming state of the cell prior to drug exposure. 
The priming state of the cell is dictated by the ratio of pro and anti-apoptotic 
proteins at the mitochondrial membrane. Interactions that modulate either the 
expression, levels, or localization of these proteins can therefore alter the 
commitment to apoptosis as a result of cellular damage. In this study I was able 
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to demonstrate that interactions with CAFs were capable of either raising or 
lowering the priming state of cancer cells, leading to altered drug sensitivity. 
Furthermore, I was able to predict the therapeutic efficacy of a drug combination 
consisting of a DNA damaging agent and a BCL-2 inhibitor based on the 
environmental context. This has huge implications in the treatment of tumors as 
the environmental context, in this case the tissue identity of the CAFs, could be 
used as a biomarker to inform what drug or drug combinations should be used in 
that specific patient.  
 
What are the molecular mechanisms underlying the change in apoptotic priming? 
 As previously mentioned in chapter 4, CAFs interact with cancer cells in a 
variety of methods, making it challenging to identify specific molecular 
mechanisms. I attempted to attribute the priming mediated sensitization 
phenotype to the expression of the cytokine IL8 but was unable to observe a 
change in the apoptotic threshold in cells treated with recombinant IL8 protein. I 
hypothesize the multiple factors are involved in altering the apoptotic threshold. I 
would test the ability of conditioned media derived from sensitizing fibroblasts to 
alter apoptotic priming. If conditioned media is not capable of altering priming, I 
would move to test the other methods of CAF interacting with cancer cells such 
and matrix protein depositions. Depending on the method of communication 
between the CAFs and cancer cells, novel therapies could be developed to treat 
cancer. For example, if a desensitizing interaction is mediated by binding to a 
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specific matrix protein, an antibody-based approach to block the interaction can 
be employed to sensitize the cancer cells to cytotoxic agents. The tissue 
specificity of the phenotype suggests that the molecular mechanisms might also 
be tissue specific. This would be beneficial in the treatment of metastatic tumors 
or primary tumors in a difference tissue type, since expressing a different tissue 
specific protein would preferentially sensitize the cancer cell over causing any 
gross changes to the normal tissue.  
 
Therapeutic implications of fibroblasts modulating apoptotic priming. 
BCL-2 inhibitors are a new class of drugs that are currently being 
investigated as potential chemotherapeutic agents. The rationale behind the 
development of BCL-2 inhibitors was the observation that many cancers 
upregulate the BCL-2 family of proteins. BCL-2 family proteins play an important 
role in regulating the initiation of apoptosis by inhibiting pro-apoptotic proteins. It 
was hypothesized that the upregulation of the BCL-2 family was leading to 
chemo-insensitivity in cancers and that inhibiting the function of these proteins 
would re-sensitize cancer to DNA damaging chemotherapeutics. It has been 
shown that BCL-2 inhibitors, such as ABT-737, have been effective in increasing 
the sensitivity of non-small cell lung cancer using in vivo xenograft mouse 
models.  
 In my thesis I see a similar sensitization of the TNBC cell line BT20 grown 
in mono-culture when treated with a combination of the DNA damaging agent 
117 
 
teniposide and the BCL-2 inhibitor ABT-737. This is shown by a synergistic 
combination index, indicating that the drugs in combination are more effective at 
killing the cells than expected based on the responses observed when the drugs 
are given individually. This phenotype is enhanced when the culturing 
environment is changed to co-culture with uterine derived fibroblasts that 
sensitize TNBC cells to DNA damage. However, when the TNBC cells are co-
cultured with adrenal derived fibroblasts that induce a desensitizing effect to DNA 
damage, the synergistic effect between ABT-737 and teniposide is lost and turns 
antagonistic. This can be explained by the fibroblast mediated anti-apoptotic 
effect being greater in magnitude than the BCL-2 inhibitor mediated pro-apoptotic 
effect, rendering ABT-737 ineffective.  
 The observed environmental dependent effectiveness of ABT-737 is an 
important feature that should be noted when designing combination therapies for 
patients with TNBC. Combination therapies between ABT-737 and DNA 
damaging agents will be effective only in environments that have a neutral or 
sensitizing effect on apoptotic priming, such as a primary tumor in the breast 
environment or a metastatic tumor in the uterine environment. However, this 
combination therapy would be ineffective against tumors that follow the common 
metastatic pattern of TNBC and grow in drug desensitizing environments such as 
the lung, liver, or bone. 
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What are the mechanisms involved in the drug specific and environmental 
independent interactions observed? 
 Not all cancer-fibroblast-drug interactions that change drug response act 
through modulating apoptotic priming. There are striking drug specific but 
environment independent interactions, such as interactions involving vinblastine 
or mitoxantrone. The environmental indifference of these interactions suggests 
that the mechanism altering drug response is independent of the change in the 
apoptotic threshold. I hypothesize that these drugs are activating a cell death 
pathway besides apoptosis, therefore they are insensitive to changes in priming. 
This would have potential therapeutic advantages as a combination therapy with 
these two classes of drugs kill cells that have become resistant to apoptosis.  
 
Advances in understanding the microenvironmental regulation of TNBC drug 
response.  
The work presented in this thesis has added to the field of 
microenvironmental regulation of cancer cell chemosensitivity. While previous 
studies have investigated the effect of fibroblasts on cancer cell chemosensitivity, 
the bulk of the data focused on targeted agents. In my thesis I demonstrated that 
the desensitizing effect that was previously observed with targeted agents is also 
observed with DNA damaging agents. The underlying mechanism of this change 
in sensitivity is due to modulation of apoptotic priming. I also demonstrated that 
fibroblasts can sensitize TNBC cells to chemotherapeutics, a surprising finding 
119 
 
as the current literature describes fibroblasts as being desensitizing influencers. 
My data also shows that the direction fibroblasts alter drug response is correlated 
with whether the fibroblasts were derived from common TNBC metastatic 
tissues. This finding offers new thoughts into why TNBCs are constrained to four 
metastatic sites following neoadjuvant chemotherapy, the chermoresistant 
influence of the fibroblasts allow micrometastases to survive treatment, as well 
as opens new avenues for the development of breast cancer therapies.  
The data presented in my thesis concerning the change in apoptotic 
priming and the use of BCL-2 inhibitors also adds another dimension to data 
previously described by the Polyak group. Marusyk et al. demonstrated that BCL-
2 inhibitors decreased the fibroblast mediated desensitization to 
chemotherapeutics and advocated the use of BCL-2 inhibitors in combination 
with the targeted agent lapatinib. However, when I investigated the use of BCL-2 
inhibitors used in combination with DNA damaging agents I found that the 
combination therapy was antagonistic in conditions where cancer cells were co-
cultured with fibroblasts derived from common metastatic tissues. This is an 
important distinction because the combination of BCL-2 inhibition and DNA 
damage would not be effective in treating metastatic TNBC tumors. One 
difference between the assays used in Marusyk et al. and my thesis is that 
Marusyk et al. recovered the cancer cells from the 3D co-culture before 
performing the priming assay while I performed the priming assay on cancer cells 
in co-culture with fibroblasts. This difference in the protocol could indicate that 
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there is a rapid expression state change when cancer cells are removed from co-
culture with fibroblasts and that there needs to be constant signaling from 
fibroblasts to stay in the drug desensitized state. The data and conclusions 
presented in this thesis are important in the development of combination 
therapies that would be effective in treating metastatic TNBC. 
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APPENDIX A: Studying Cellular Signal Transduction with OMIC 
Technologies 
 
Appendix A was taken almost verbatim from:  
Landry BD, Clarke DC, Lee MJ. Studying Cellular Signal Transduction with 
OMIC Technologies. J Mol Biol. 2015;427(21):3416-3440. 
doi:10.1016/j.jmb.2015.07.021. 
 
 
Abstract: 
In the gulf between genotype and phenotype exists proteins and, in 
particular, protein signal transduction systems. These systems use a relatively 
limited parts list to respond to a much longer list of extracellular, environmental, 
and/or mechanical cues with rapidity and specificity. Most signaling networks 
function in a highly nonlinear and often contextual manner. Furthermore, these 
processes occur dynamically across space and time. Because of these 
complexities, systems and “OMIC” approaches are essential for the study of 
signal transduction. One challenge in using OMIC-scale approaches to study 
signaling is that the “signal” can take different forms in different situations. 
Signals are encoded in diverse ways such as protein-protein interactions, 
enzyme activities, localizations, or post-translational modifications to proteins. 
Furthermore, in some cases signals may be encoded only in the dynamics, 
duration, or rates of change of these features. Accordingly, systems-level 
analyses of signaling may need to integrate multiple experimental and/or 
computational approaches. As the field has progressed, the non-triviality of 
integrating experimental and computational analyses has become apparent. 
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Successful use of OMIC methods to study signaling will require the “right” 
experiments and the “right” modeling approaches, and it is critical to consider 
both in the design phase of the project. In this review, we discuss common OMIC 
and modeling approaches for studying signaling, emphasizing the philosophical 
and practical considerations for effectively merging these two types of 
approaches to maximize the probability of obtaining reliable and novel insights 
into signaling biology. 
 
Introduction: 
A cell's ability to perceive and understand its surroundings, respond to 
changes in the environment, and/or adapt to defend homeostasis is governed by 
complex signal transduction systems. In plain terms, the basic purpose of 
signaling is to relay information about the outside of the cell to the nucleus. This 
signaling often results in alterations to the transcriptional state of the cell as to 
modify cellular behavior100. The state of the signaling network creates the 
background “context” that is often missing in genomic studies of behavior/drug 
response/disease outcome, which has substantially limited our ability to leverage 
genomic or transcriptomic insight for therapeutic benefit. Decades of research 
have identified signaling pathways that control essentially every cellular function 
(growth, migration, death, differentiation, division, secretion, etc.). Owing to this 
fact and because these systems typically include many “drug-able” components, 
signaling has emerged as a common target in modern molecular medicine. 
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However, after a decade or so of optimism, it has become clear that the 
pharmacological targeting of signaling often results in unanticipated 
consequences, which manifest clinically as toxicity, acquired resistance, and/or 
limited efficacy. Progress in the area of targeted (or “personalized” or “precision”) 
medicine will likely require a more refined understanding of how signaling 
pathways function, how they are altered in disease states, and how they are 
augmented by drug therapies. 
The complexity of signal transduction networks demands “systems-level” 
approaches, but answering this demand remains a major challenge. Signaling 
networks are densely interconnected, which facilitates signaling “crosstalk” (i.e., 
pathway activities influence each other), and most forms of crosstalk are 
incompletely understood. Furthermore, the “architecture” of a signaling process 
(i.e., the connectivity or wiring of the signaling circuit) is regulated dynamically 
and can change through time. This rewiring or reprogramming of signaling 
networks is a concept that is only now being explored in a systematic way54,101. 
Finally, the information content (i.e., the signal) takes different forms in different 
situations. Thus, no single OMIC method is appropriate for the comprehensive 
study of signaling. In canonical examples, the signal is encoded and transmitted 
by the absolute levels of a protein or post-translationally modified form of a 
protein. Additionally, signals are also encoded by the location of a protein; the 
interactions between proteins; the relative stoichiometry of positive and negative 
regulators; and even the rate, duration, or patterns of change between these 
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states (Fig. A.1). Moreover, if the future continues to reaffirm recent precedent, 
these “complex” forms of signaling will prove to be commonplace. 
 
Because signaling has long been acknowledged as being complex, many 
systems biology approaches have been applied to their study. In the early days, 
the typical approach was to generate a large amount of data using the latest 
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OMIC technology (e.g., microarray) and to apply whatever computational 
approach was currently the “hottest”, followed by believing that new insights 
would inevitably emerge from the modeling. This philosophically problematic 
approach was exacerbated by the practical difficulties of these two steps often 
being performed by different people in different laboratories whose 
communication was likely impaired by differences in field-specific jargon and 
culture, as well as more fundamental differences in intellectual goals. Since these 
early efforts—which we call version 1.0 of systems biology of signal 
transduction—the field has matured considerably. Systems approaches featuring 
“OMIC” data and computational modeling are and will continue to be instrumental 
in the study of signaling. However, it is clear that their successful implementation 
requires careful planning and consideration of the respective strengths and 
weaknesses of the experimental and computational strategies not only in 
isolation but also in relation to each other. In this review, we will cover different 
ways that a systems biologist can collect and model signaling data. We will cover 
some recent examples from the literature and discuss in detail some common 
pitfalls and practical considerations for successfully integrating OMIC data with 
computational approaches in signaling research. 
 
Methods for High-Throughput Collection of Quantitative Signaling Data: 
The creation of robust and precise models relies on the generation of 
accurate data sets that measure how signals in the cell are conveyed. High-
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throughput methodologies have facilitated the generation of reliable large-scale 
data sets for a wider variety of signals. Because signals are encoded in different 
ways, many different technologies are necessary to measure the propagation of 
a signal throughout the cell. Methods include those that are based on “molecular 
profiling” of protein signaling states and those based on “molecular perturbation” 
and inference102. In this section, we will review various assays used to collect 
signaling data, discuss the advantages and limitations of each method, and also 
discuss practical considerations in the design of OMIC experiments for 
interrogating signaling. An overview of these approaches is also available in Fig. 
A.2. This section will be formatted around four basic ways in which signals are 
encoded: the levels, interactions, localizations, and activities of various signaling 
proteins103. 
 
Measurement of protein expression and post-translational modification 
levels. 
In the simplest situations, the signal is encoded by the mere existence or 
non-existence of a post-translationally modified form of a protein or, more rarely, 
the total expression level of a protein. Several methods exist for quantifying 
protein levels, but only one, mass spectrometry, can be argued to provide 
comprehensive OMIC-scale depth. 
127 
 
128 
 
129 
 
130 
 
131 
 
 
132 
 
Mass spectrometry 
To many, the gold standard in proteomics is mass spectrometry. Unlike 
any other proteomic technologies, mass spectrometry can be used to measure 
complete proteomes and thousands of post-translationally modified proteins, 
rivaling the depth and richness of other genomic technologies. Furthermore, 
these measurements are precise and quantitative, and these obviate the need to 
rely on the existence of specific antibodies (although antibodies are often used in 
mass spectrometry experiments to enrich for protein fractions of interest). By 
using cellular fractionation techniques or enrichment of proteins by 
chromatographic or other methods, it is possible to comprehensively and 
quantitatively study the global protein landscape, specific subsets of proteins, or 
proteins belonging to certain cellular compartments. For example, mass 
spectrometry has been used to study the global ubiquitin proteome by 
immunoprecipitating ubiquitin104, phosphotyrosine proteomes by using pan-
phosphotyrosine antibodies105, and autophagy-regulatory proteins by 
precipitating proteins involved in vesicle trafficking106. These insights have 
provided a comprehensive parts list for important regulatory functions in biology. 
One particularly exciting application of mass spectrometry in signaling 
research is the use of multiplex kinase inhibitor beads107. In MIB-MS (mass 
spectrometry of multiplex kinase inhibitor beads), a cocktail of inhibitors that 
promiscuously bind to many kinases are conjugated to beads and mixed with 
protein lysate. Several inhibitors are used to target the majority of the expressed 
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kinome. The binding of a particular kinase to the bead occurs as a function of the 
kinase's native affinity for the inhibitor and its level of expression, as well as the 
level of kinase activity, since kinase inhibitors bind preferentially to activated 
forms of kinases. Thus, differential binding between experimental conditions can 
be inferred in most cases to reflect differences in kinase activity. Duncan et al. 
used MIB-MS to profile kinome activity in breast cancer cells revealing total 
kinome reprogramming following targeted MEK inhibition101. In addition to these 
multi-inhibitor conjugated beads, others have used covalent kinase inhibitors in a 
similar manner. Activity-based proteome profiling uses small-molecule probes 
designed to react with nucleophilic residues, most typically with cysteine, near 
the kinase active site to form irreversible covalent interactions. These activity-
dependent interactions can be specific for target kinases, although recent 
research suggests that off-target binding to both kinases and non-kinase proteins 
can be problematic108. 
While powerful, some issues do potentially exist for the use of mass 
spectrometry in the study of signal transduction. For example, decoding mass 
spectra to reveal peptide identity is non-trivial in general, and this may be 
worsened in signaling studies because many signaling proteins share similar 
domains, some of which have very similar and sometimes identical peptide 
sequences. Excellent software exists to aid in peptide identification; however, 
many of these statistical tools may be underestimating false discovery rates, 
sometimes dramatically so109,110. Furthermore, mass-spectrometry-based 
134 
 
proteomics is relatively slow, expensive, and does not scale well to the analysis 
of hundreds or thousands of samples that can easily emerge from studies 
involving many ligand doses, experimental time points, and other perturbations. 
Undoubtedly, many of these issues will ultimately be resolved. Mass 
spectrometry is a mature but ever-changing technology with many different 
specific iterations. For example, while mass spectrometry typically subsamples 
the input protein, recent studies report deep, even full, proteome depth111. Also, 
when proteomes are subsampled, comparisons between samples are made non-
trivial, but these comparisons can be made using labeling methods such as 
SILAC112, using isobaric mass tags, or in label-free approaches with the aid of 
computational tools113. Recent advances in targeted mass spectrometry have 
increased the specificity and sensitivity of target identification and analysis114. 
 
Immunoblotting 
Traditional methodologies based on Western blotting continue to be tried 
and true tools for measuring total protein levels and levels of specific modified 
forms of proteins, assuming suitable antibodies exist (see note below on 
antibody-based proteomics). Using various biochemical separation and/or 
immunoprecipitation techniques, it is also possible to quantify protein localization 
to various subcellular compartments or interactions between proteins and other 
proteins or biomolecules. These tools are often comforting to biological scientists 
both because of their familiarity and because visualization of a band of predicted 
135 
 
size on a gel provides assurance that the antibody is reporting the correct 
protein. If paired with an appropriate analysis platform—one with a large dynamic 
range that is confirmed to be linear or whose non-linearities can be fit to a 
standard curve—these approaches can be quantitative115. Although the 
multiplexing capabilities on immunoblots are limited to two or three parallel 
measurements, the relatively low cost of these approaches allows throughput to 
be achieved through repetition, particularly when the lysate material is abundant. 
Also, modern commercially available platforms have dramatically shortened the 
gel electrophoresis and transfer durations, such that it is feasible for a single 
operator to analyze hundreds of samples per day, each for dozens of specific 
analytes. Immunoblotting remains a common tool for validating and precisely 
studying single proteins or even small protein networks or as complementary 
methods to “fill in the gaps” left by other high-throughput techniques. For most 
applications, however, these approaches simply lack the throughput necessary 
for generating comprehensive OMIC-scale quantitative data sets. 
 
Protein lysate microarrays 
A higher-throughput approach that uses the same intuitive design as 
immunoblotting is lysate microarrays116. In these approaches, antibodies are still 
needed in order to quantify the levels of proteins or modified protein species. 
These approaches utilize robotic tools to print material in regular patterns, 
typically on a smaller and denser scale that could be achieved by hand. Analysis 
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of protein lysates in this miniaturized format requires much less biological 
material than standard approaches, and it uses dramatically reduced amounts of 
expensive reagents such as antibodies. Two basic formats exist: forward- and 
reverse-phase arrays. Forward-phase arrays are constructed by printing capture 
antibodies on a flat surface and by flowing a cellular lysate over the printed 
antibody chip. In this approach, a second antibody is typically then applied to 
determine the level of protein captured by the immobilized antibody. While this 
approach negates the need to label the lysate material, multiple specific 
antibodies that can bind to the target protein without competition must exist. 
In addition to the need for multiple target specific antibodies, forward-
phase arrays also generally require relatively large amounts of protein lysate. 
Reverse-phase protein arrays (RPPAs) alleviate this issue. Here, small amounts 
of protein lysates (approximately picogram range) are spotted and dried onto a 
rigid protein-binding surface such as nitrocellulose. The protein lysate array can 
then be probed and measured in a manner akin to a traditional immunoblot. 
RPPA can rapidly measure many lysates in parallel, wherein “multiplexing” is 
achieved through repeated printing of lysates onto parallel arrays and probing 
with different antibodies. RPPAs are likely the most cost effective and the 
highest-throughput solution for experiments that include many samples 
(approximately 100–10,000 +) with relatively few target analytes of interest 
(dozens to hundreds). For example, a single array can be printed to include 
thousands (even 10,000–100,000 +) of individual lysates, which may represent 
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different cell types, drug treatments, time points, patient samples, and so on. 
Once printed, RPPAs essentially function similarly to high-throughput “dot blots”, 
and they share many of the same benefits and limitations. For example, RPPAs 
omit the electrophoresis step used in immunoblotting. This omission reduces 
assay time but also can increase non-specific antibody binding, which limits 
dynamic range and assay sensitivity. Thus, antibodies used in RPPA need to be 
validated carefully117,118. A modification to the RPPA method that may improve 
sensitivity is the micro-Western array119. The central difference between these 
methods is that cell lysates are printed onto a gel and undergo a short semi-dry 
electrophoresis step before being transferred to a membrane and probed with 
primary and secondary antibodies. The short electrophoresis step may separate 
competing epitopes and may allow for resolution of the specific protein bands, 
assuming that non-specific binding proteins migrate differently (i.e., are of a 
different size)120. 
In spite of some obvious limitations, many antibodies have been carefully 
validated and hundreds of protein targets can be studied currently using 
RPPA121. Many researchers have used RPPA and other array-based methods to 
study signaling, particularly in cancer biology. For example, RPPAs are used to 
analyze primary human tumor samples as a part of the Tumor Cancer Genome 
Atlas122. Considering the limited amounts of patient material available for each 
sample and the relevance of signaling proteins in targeted medicine, RPPA plays 
a critical role in this analysis. In another example, Federici et al. recently used 
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RPPA to interrogate signaling pathway activation states of all cell lines in the 
NCI-60123. Their pathway activation mapping approach revealed several 
phenotypes that were common to subsets of the NCI-60 cell lines and 
transcended typical organ-type distinctions. By integrating these data with other 
OMIC data for coding and non-coding RNAs and genomic features, they were 
able to identify functional networks that significantly improved prediction of drug 
sensitivity compared to traditional approaches that use only genomic or 
transcriptomic features. 
 
Multiplexed flow cytometry, mass cytometry, and bead-based assays 
For many signaling proteins, the population expression or activity levels 
measured in bulk lysates can be deceiving. For example, at the single-cell level, 
some signaling systems only exist in “on” or “off” states and graded population 
responses actually reflect differences in the percent of cells that are “on” and not 
the degree to which the pathway is “on”. This scenario is not only obviously true 
for binary signals or “all-or-none” processes such as cell death124 but also true for 
other processes that may intuitively appear more graded than binary. In fact, 
even in unimodal distributions, cell-to-cell heterogeneities can be substantial and 
can underlie divergent behaviors, including sensitivity and resistance to 
drugs125,126. Flow cytometry is probably the most widely used assay to 
quantitatively study signal transduction with single-cell resolution. The basic 
workflow is similar to other antibody-based techniques, although cells are first 
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fixed as individual cellular units, before permeabilization and labeling with 
specific antibodies. Labeled cells are passed in single file through a flow cell 
where fluorescence intensity, cell size, and cellular internal complexity can be 
measured. In OMIC applications, flow cytometry suffers from two basic 
weaknesses. First, this is not a high-throughput method, since sample 
preparation and read time can be quite extensive, particularly for adherent cells. 
Second, multiplexing of measurements is limited by the available fluorescent 
spectra. Using advanced machinery and careful fluorescence compensation, one 
can multiplex more than a dozen measurements127, but most users measure 1–
12 signals per sample. 
To improve upon the multiplexing limitations of traditional flow cytometry, 
Scott Tanner and colleagues coupled the single-cell profiling capabilities of flow 
cytometry to the exquisite sensitivity of mass spectrometry128. Mass cytometry 
uses antibodies conjugated to rare-earth metals, typically those in the lanthanide 
series, instead of fluorophores129. Samples are first processed using flow 
cytometry techniques to create a stream of single cells, which are subsequently 
vaporized into single-cell droplets. The amount and identity of the bound antibody 
is quantified using a mass spectrometer to detect differences in mass 
corresponding to the different atomic masses of the rare-earth metals. Using 
mass cytometry, one could theoretically analyze more than 100 unique analytes 
in a single cell, but currently, 30–50 distinct signals are feasibly analyzed 
simultaneously. Mass cytometry is still nascent technology but has already 
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transformed our understanding of immune cell development. In a recent 
publication, Nolan and colleagues used mass cytometry to label 34 parameters in 
human hematopoietic cells, including surface and intercellular proteins130. Their 
analyses revealed previously unknown relationships between precise signaling 
states and well-characterized hematopoietic cell subtypes and revealed a more 
refined view of hematopoietic stem cell developmental trajectories. 
While mass cytometry offers impressive multiplexing capabilities, other 
flow-based approaches can expand multiplexing capability by an order of 
magnitude although not with single-cell resolution. Multiplexed-bead-based 
assays (like those sold commercially by Luminex) combine antibody labeling with 
laser-based cytometry. Here, polystyrene or magnetic beads are filled with 
specific ratios of two or three dyes, creating a colorimetric signature analogous to 
a barcode used in genomic or RNA-sequencing methods. Each uniquely colored 
bead is then conjugated to an antibody against a specific protein such that 
measured fluorescence levels can be attributed to the specific protein of interest. 
This technology allows for the concurrent measurement of 500 simultaneous 
signals per sample, although antibody cross-reactivity typically limits the 
multiplexing capability well below this threshold. Using this method, Du et al. 
recently profiled nearly all tyrosine kinases in hundreds of cancer cell lines, each 
treated with dasatinib, an inhibitor of the tyrosine kinase Src131. A similar strategy 
was also used to increase the throughput of transcriptome profiling. In this case, 
antibodies were replaced with oligonucleotide probes for each of 1000 
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“landmark” genes, which allowed inference of genome-wide transcriptional states 
at a fraction of the cost of traditional array or sequencing methods132. 
 
Caveats in antibody-based proteomics 
Essentially all of the abovementioned approaches rely on the existence of 
high-fidelity antibodies to detect the specific epitopes of interest, and a 
discussion of their use must consider the main limitation: the lack of reliable 
antibodies for most protein targets133. Also, with the exception of immunoblotting, 
the other methods all attempt to bind to a target epitope without an 
electrophoresis step to remove other competing off-target binding sites. Thus, the 
proportion of available antibodies that produce reliable signals in these high-
throughput platforms is only a fraction of the antibodies that produce reliable 
signals in immunoblots. Estimates vary, but generally between 1% and 10% of 
antibodies that work in immunoblots will work in the other methods we discussed. 
Also, because most methods do not produce a visible band on a gel, additional 
measures should be taken to validate that the signal is reporting the levels of the 
correct protein. When validating antibodies for RPPA, for example, we previously 
used a two-step protocol. We began first by testing antibodies in RPPA and 
identifying those that reported a dynamic range of at least 1.5-fold across 90 
generic control conditions, which were designed to feature positive and negative 
controls for all targets of interest. In a second phase, we retested that small 
subset of antibodies in immunoblot format to confirm that the change in signal 
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occurred in a protein of correct predicted size and that the two methods produced 
correlated data54. Additionally, antibodies that are accurate when used in 
isolation may not produce reliable signals when multiplexed with other antibodies 
due to cross-reactivity; thus, the reliability of measurements derived from highly 
multiplexed platforms should be tested and validated rigorously. 
 
Methods to measure protein–protein interaction. 
Many post-translational modifications or activated signaling proteins cause 
conformational changes or the creation of new binding domains, resulting in 
regulated protein–protein interactions. Thus, measuring the extent to which 
proteins interact can indicate signaling pathway activity, and identifying new 
binding partners may reveal new proteins involved in signal regulation. Below is 
an overview of common tools used to measure protein–protein interaction in high 
throughput. 
 
Yeast 2-hybrid (Y2H) assays 
The yeast 2-hybrid system is a classic approach to identify protein–protein 
interactions134. This approach takes advantage of the modularity of many 
transcription factors, which have two separable functional domains that confer 
DNA-binding and transcription-activating functions. In Y2H, a protein of interest is 
fused to the DNA-binding domain while a protein or library of proteins to be 
screened are fused to the corresponding transcriptional activation domain. 
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Protein–protein interaction can then drive transcription of a reporter gene135. 
There are several caveats to this method. Non-physiological false-positive 
interactions can occur either due to overexpression of the screened proteins or 
because proteins are forced to co-exist in the nucleus that may not typically 
reside in a shared subcellular compartment. Also, false negatives can occur. Y2H 
will often miss dynamically regulated interactions or interactions that require a 
post-translational modification that may be lacking in yeast or not properly 
regulated in the assay. Also, since the readout for binding occurs in the nucleus, 
only proteins that can accommodate nuclear localization can be screened. 
Y2H screening can be performed in high throughput, even on a 
comprehensive scale. Using Y2H, Vidal and colleagues have recently published 
the first full-proteome-scale map of the human protein–protein interaction 
network136. This systematic analysis has doubled the list of known/potential 
binary interactions, and strikingly, their analysis has revealed that the interactions 
identified by systematic Y2H are free from a bias toward well-studied proteins 
existing in the established interactome. Thus, this data set is certain to include 
clues into many unexplored functional relationships. 
 
Membrane Y2H, MaMTH, and other protein complementation assays 
The nuclear localization of traditional Y2H assays can be a severe 
limitation for some aspects of signal transduction. Transmembrane proteins, for 
example, play important roles in signaling as the primary signal relay between 
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the cell exterior and interior, and regulated protein–protein interaction among 
transmembrane proteins is a major mechanism by which signals are encoded at 
the receptor layer of a signaling pathway. For example, the primary means by 
which receptor tyrosine kinase autophosphorylation transmits a signal is through 
the recruitment of proteins containing phosphotyrosine-binding domains. 
Determining binding interactions in high throughput for membrane proteins is 
challenging since they contain large stretches of hydrophobic residues and 
cannot be expressed readily in aqueous solutions. Membrane Y2H and a 
modified version that works in human cells, mammalian membrane two-hybrid 
(MaMTH), were developed to circumvent this issue and allow for high-throughput 
screening of membrane protein interactions137,138. Both assays rely on the 
concept of split ubiquitin binding. A transmembrane protein of interest is tagged 
with both the C-terminal half of ubiquitin and a transcription factor that is used to 
drive transcription of a colorimetric or fluorescent reporter protein. Proteins that 
are to be screened for binding are tagged with the N-terminal half of ubiquitin. 
Binding events between the membrane protein of interest and the screened 
protein yield the formation of a complete ubiquitin molecule, which is recognized 
by endogenous deubiquitinating enzymes, releasing the tethered transcription 
factor to drive reporter expression. Using MaMTH, Petschnigg et al. studied 
EGFR signaling in non-small cell lung cancers containing EGFR mutations138. By 
screening binding partners of the mutated receptor and comparing them to a 
wild-type EGFR signature, the investigators were able to identify a novel binding 
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protein that promotes constitutive signaling. MaMTH is a new technology that will 
certainly be used in the coming years for the study of receptor signaling and drug 
mechanism of action in human disease. 
In addition to these approaches, there exist several other methods that 
rely on the complementation of a split reporter protein, which can regain function 
when the two halves are in proximity. In addition to the use of ubiquitin or 
transcription factors, other similar strategies have used fragments fluorescent 
proteins (bimolecular fluorescence complementation)139 of the tobacco etch virus 
protease (split TEV)140, dihydrofolate reductase141, β-lactamase142, luciferase143, 
LacZ144, and many other proteins, demonstrating the versatility and 
generalizability of this technique. 
 
LUMIER 
Another commonly used method for detecting protein–protein interactions 
is co-affinity purification. To adapt this generic strategy to high-throughput 
analyses, the Wrana laboratory developed LUMIER (luminescence-based 
mammalian interactome mapping). In this method, a protein of interest is fused to 
luciferase and co-expressed in mammalian cells with target proteins fused to an 
affinity purification tag. After signal stimulation and cell lysis, interaction/co-
immunoprecipitation can be inferred through luminescence intensity. The main 
advantage of this approach over other co-immunoprecipitation-based methods is 
throughput, especially since these assays are sensitive enough to be performed 
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in microtiter plates. LUMIER was originally used to investigate transforming 
growth factor-β (TGF-β) signaling in human cells. Wrana and colleagues 
screened over 500 potential TGF-β binding partners and identified links between 
the TGF-β pathway and various other processes, such as epithelial tight junction 
regulation, which contextually help regulate TGF-β signaling145. More recently, 
Lindquist and colleagues applied the LUMIER technique to comprehensively 
study the Hsp90 interactome146 and to study the specificity of kinase inhibitors in 
living cells147. In the latter example, the authors leveraged the fact that binding of 
small molecules to kinases results in thermodynamic stabilization and thus loss 
of interaction with chaperone proteins. This study revealed critical targets of 
kinase inhibitors, including many that were unexpected. 
 
Protein chips 
In addition to protein lysate microarrays described above, many other 
types of arrays can be built to study protein biology, some of which are powerful 
tools for studying protein–protein interaction rather than expression levels148. 
Protein chips are engineered by arraying and immobilizing purified proteins or 
protein domains, instead of antibodies or lysates. Protein chips have many uses. 
For example, a protein, lipid, nucleic acid, or small molecule of interest could be 
profiled against a near-proteome-wide protein chip to reveal all potential binding 
partners149. Huang et al. used this approach to identify new components of 
mTOR signaling150, and Jones et al. used protein chips featuring nearly all 
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human Src homology 2 (SH2) and phosphotyrosine-binding (PTB) domains to 
comprehensively study protein recruitment to activated ErbB receptors151. 
 
Quantitative measurement of protein localization or protein activity. 
For many signaling nodes, the activation status cannot be inferred from 
the levels of a post-translationally modified protein or from the interactions 
between proteins. In these cases, it may be necessary to directly measure 
enzymatic activity or localization of the signaling protein of interest. In general, 
available methods can be quantitative but are not easily performed in a high 
throughput. Here, we briefly survey quantitative methods for studying protein 
activity and the dynamics of protein localization. 
 
Quantitative microscopy 
The transmission of a signal is often driven by a translocation event of a 
protein, for example, from the cytoplasm to the nucleus, or the clustering of a 
protein to the plasma membrane. Thus, for some signaling nodes, quantitative 
microscopy can be a reliable approach to monitor pathway activation. 
Additionally, microscopy may be the best approach when studying rapid signals 
or for those that occur in an oscillatory manner, as is the case for NF-κB 
signaling152 and p53 signaling153,154. Recent analyses of NF-κB signaling by 
Covert and colleagues revealed substantial heterogeneity at the single-cell level. 
These quantitative single-cell insights were instrumental in revealing the use of 
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both digital and analog features to differentially control activation of specific NF-
κB target genes152. Single-cell resolution has also been valuable for the study of 
signaling processes that are initiated stochastically. For example, a critical event 
in apoptotic cell death signaling activation is the formation of pores that 
permeabilize the mitochondria (called mitochondrial outer membrane 
permeabilization or MOMP). The timing of MOMP after cell death stimulation is 
variable but can be measured directly using fluorescence resonance energy 
transfer (FRET) sensors, fluorescent reporter constructs, or membrane potential 
dyes that localize to the mitochondria124,155. Single-cell analyses of MOMP 
dynamics have revealed a nearly invariant “switch-like” activation that is masked 
by the graded population-level responses, and computational modeling of these 
data have revealed critical features that contribute to this binary response and 
activation stochasticity156. 
Quantitative, automated microscopy is becoming increasingly available as 
microscopes have become better and cheaper. Image processing and 
quantification, however, remain major challenges in the use of quantitative 
microscopy. Several freely available image analysis programs exist to aid in 
quantitative image analysis, including CellProfiler157, PhenoRipper158, 
ImageRail159, and ImageJ160. 
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In vitro kinase and other in vitro enzyme assays 
In many kinases, phosphorylation on the activation loop can be used 
safely to indicate kinase activity. Unfortunately, this feature is occasionally 
misinterpreted to assume that all phosphorylation events on kinases modulate 
their activity. Most phosphorylation on kinases do not alter their kinase activity 
and many kinases do not require activation-loop phosphorylation to become 
active. Furthermore, for many kinases, good activation-loop antibodies do not 
exist. Thus, the only universal method for determining the activity of all kinases is 
to measure it directly. In vitro kinase assays have been traditionally performed 
using purified proteins or cell lysates incubated with radioactive isotopes and 
purified substrate proteins or peptides. These assays are reasonably 
straightforward, do not require much specialized equipment, and can be 
performed in a medium to high throughput with very little material161. Because 
many kinases are promiscuous, these assays often need to be conducted in the 
presence of inhibitors or following enrichment or purification. Accordingly, these 
assays likely cannot be performed at a comprehensive OMIC scale. Thus, most 
practical applications will use in vitro enzyme assays to study single proteins and 
very small networks or as a complementary assay in conjunction with other 
approaches. For example, Janes et al. used in vitro kinase assays in conjunction 
with immunoblotting and antibody arrays to study contextual dependencies in 
cytokine-induced apoptosis162. Recently, the Gygi laboratory has developed high-
throughput methods to directly monitor kinase activity against synthetic 
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substrates in vitro using mass spectrometry163. This approach, called KAYAK 
(kinase activity assay for kinome profiling), uses synthetic peptides featuring 
motifs for known kinases. Arrayed or pooled peptides are mixed with cell lysates 
and the acquisition of peptide phosphorylation is quantified by mass 
spectrometry following some enrichment steps. This approach was used to 
quantify the activities of 90 kinases across various treatment conditions in many 
different cell lines. 
Of course, kinases are not the only enzymes and most enzymes can be 
purified and studied biochemically in the cell-free in vitro environment. For 
example, in vitro biochemical assays are a common method for studying the 
activity of GTPases, which do not leave a physical “mark” on their substrates. 
Methods that have sufficient throughput and coverage to be considered “OMIC” 
approaches are rare, but some exist and certainly others are in development. For 
example, assays have been developed to facilitate high-throughput quantification 
of phosphoprotein-specific phosphatase activity164, as well as matrix 
metalloprotease activity165. 
For most in vitro enzyme assays, the main limitation to throughput is the 
need to purify specific proteins. Activity-based probes and chemical sensors 
provide an excellent alternative when available. One example is sensors that 
exploit the chelation-enhanced fluorescence of sulfonamido-oxine (Sox) 
chromophores, which increase in fluorescence when bound to Mg2 +166. These 
chromophores can be conjugated to peptides containing phosphorylation motifs 
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for a kinase of interest and engineered in such a way that Mg2 + binding requires 
peptide phosphorylation. In addition to Sox chromophores, there exist other 
fluorophores and dyes whose fluorescence properties are sensitive to the 
microenvironment in which they are bound167,168. These reagents are particularly 
valuable for studying signals transmitted through G proteins, which transmit 
signals only by virtue of a small conformational change upon GTP binding. 
Because their activation cycles in vivo are short and their interactions with 
substrates are relatively weak, this large and important class of signaling proteins 
has been traditionally difficult to study in the context of living cells. FRET-based 
activity probes were used by Klaus Hahn and colleagues to visualize the location 
and dynamics of RhoA activation in living cells169. These studies revealed distinct 
spatiotemporal patterns of RhoA activity in response to different extracellular 
cues, revealing a previously unappreciated level of richness in signaling diversity. 
 
Inference of pathway activity through transcription or functional genomics 
When collecting signaling data, it is not always possible (and sometimes 
not necessary) to view the signal at each node as it is transmitted through a 
network. In these cases, an endpoint measurement of network activation may be 
a sufficient substitute. Most stimuli-dependent signaling events result in a change 
in transcriptional states, whether to activate or repress certain genetic programs. 
A transcriptional readout can be used to infer the signaling state of a cell using 
microarray, RNA sequencing, or microfluidic technologies that allow for high-
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throughput quantitative PCR132. These approaches are quantitative, are high 
throughput, and can be performed on a comprehensive scale. The main limitation 
is the difficulty in relating a particular transcriptional state to the activation or 
inhibition of a discrete signaling protein. Some computational approaches exist to 
aid in this effort. The most widely used would be GSEA (gene set enrichment 
analysis)170. GSEA uses a rank-ordered list of differentially expressed genes to 
identify enrichments or depletions of a priori defined genetic “signatures” (i.e., 
cohorts of genes that are somehow related to each other or to a biological 
process). This approach is not formally restricted to the study of signal 
transduction, but its application to signaling research is possible by using 
signatures that report signaling states. Additionally, the Califano laboratory has 
invented several approaches for reverse engineering regulatory networks using 
transcriptional profiles171–173. Most of these algorithms focus on transcription 
factor activity rather than on the activity of upstream signaling proteins, but in 
many cases, the “master regulators” identified are proteins with defined roles in a 
signaling circuit. Inference algorithms that use proteome data rather than 
transcriptome data also exist. The Linding laboratory has developed several 
approaches that use mass spectrometry data to infer the connectivity of signaling 
networks174. 
In addition to transcription- and mass-spectrometry-based methods, 
functional genomics can be used to infer signaling mechanisms. Several 
screening approaches are common in biological research, including the use of 
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specific drugs or small molecules, shRNA/RNAi, or the clustered regularly 
interspaced short palindromic repeat-based genome editing CRISPR175,176. 
These perturbations can be paired with simple measures of pathway activation 
(even at a single node) to reveal functional signaling networks. Screens can be 
performed in a high-throughput manner but hits typically need to be validated by 
an independent method due to high potential for off-target effects. With all 
inference-based approaches, observed phenotypes will be a mixture of direct, 
indirect, and compensatory effects. Deconvoluting these effects can be 
challenging particularly because signaling proteins typically have multiple roles in 
different contexts and are shared in many different processes, creating extensive 
crosstalk. Functional genomics are ideally suited for revealing a molecular “parts 
list”. However, these approaches do not typically result in sufficient 
understanding of pathway structure, which may be needed to make reliable 
predictions about how cells will behave following pathway stimulation or inhibition 
at various nodes. Thus, these approaches are best used in combination with 
more direct measures of signaling activity and in close partnership with 
computational approaches. 
 
Experimental design for OMIC experiments: Basic principles and practical 
considerations. 
Experimental design is an important issue in all areas of research, but 
some special considerations are needed in OMIC experiments due to their size 
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and complexity. Additionally, OMIC experiments are expensive, with a single 
experiment often costing thousands of dollars. These experiments therefore 
demand effective and efficient designs and error-free execution because they are 
not feasibly redone. Several features that are common to OMIC experiments, like 
the use of multiwell plates, can create strong batch effects177. Proper 
experimental design is necessary to minimize and remove, or at least identify, 
these problems. In the early days of “big data” science, some practitioners held 
the view that OMIC experiments could be held to a different, maybe lower, 
standard of experimental rigor (leaving out some controls, not performing 
biological or technical replicates, etc.). These decisions were often made based 
on cost feasibility and also with the idea that data generated were just “a screen” 
and would be validated carefully afterwards. If these ideas did not seem crazy at 
the time, they certainly should now. Large signaling data sets are not being used 
solely as unvalidated resources but are also used by computational biologists to 
aid in model parameterization or by pharmaceutical companies to motivate drug 
development programs178–180. Implementing the basic principles of sound 
experimental design and including all necessary controls are essential steps for 
minimizing bias and maximizing interpretability and reliability of OMIC 
experiments. Experimental design principles for proteomics experiments have 
been reviewed in detail elsewhere181–184 and Glass has presented a valuable 
discussion of the various types of controls needed to interpret biological 
experiments185. In this section, we briefly highlight some key concepts. 
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A major challenge of biological experimentation is separating signal from 
noise. In statistical terms, the experimental signals represent biological sources 
of “variance”, that is, changes in the measured signal caused by the experimental 
treatments, which the experimenter seeks to quantify. The noise of an 
experiment will likely arise from two principal sources: bias and random error. 
Bias is the systematic deviation of the measured effect from the “true effect”. 
These deviations can be attributed to both technical and biological sources and 
presumably the experimenter only cares about the latter. Random error refers to 
the unsystematic errors that enter the experiment due to unknown sources, 
which reduce the precision of the measurements and the ability to detect 
treatment effects. In OMIC experiments, because the operator cannot optimize 
each analyte, data point, or assay individually, the signal-to-noise requirements 
will be likely more stringent than for a low-throughput assay that can be more 
easily fine-tuned per experiment. 
The three universal principles of sound experimental design are 
randomization, blocking, and replication. Randomization is a process that is 
applied in two contexts: first, experimental units are allocated to treatment groups 
with equal probability; second, experimental units are treated (and the resulting 
samples processed) in a random order. Randomization helps to reduce bias by 
minimizing the probability that experimental units with similar characteristics are 
assigned to the same treatment group. Randomization also helps satisfy the 
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necessary condition of independence, which is a common assumption in most 
statistical tests. 
Blocking refers to the allocation of treatment groups into experimental 
units or “blocks”. Blocks are subgroups of experimental units that exhibit less 
variance within groups than between groups. An example of an experimental 
block in an OMIC experiment is each 96-well assay plate within an experiment 
that features multiple plates or each sequencing lane in a RNA-sequencing 
experiment. In multiwell plates, even the well location represents a potentially 
confounding block. Despite the experimenter's best efforts to treat them equally, 
each block is processed at a different time, which may introduce a systematic 
variance. These block or “batch” effects are prevalent in OMIC experiments177. 
Defending against batch effects requires the use of blocking strategies in which 
replicates from the same treatment group are distributed across different plates 
(and preferably in different locations on a plate) rather than loaded together on a 
single plate, in order to ensure that the batch effect does not confound the 
biological effect. 
Replication is the repeated treatment and/or assaying of multiple 
experimental units. Replication is needed for precise and accurate results, for 
generalizing the results of the sample to the population from which it was drawn, 
and for generating statistically powerful tests. Two replicate types are commonly 
featured in OMIC experiments: biological and technical. Some ambiguity exists in 
the community for what constitutes a biological versus technical replicate186, but 
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in most instances, a biological replicate represents an experimental unit that was 
treated independently of the other units. Examples include each animal of a 
mouse experiment or each dish of cells in a cell-culture-based experiment. 
Technical replicates consist of samples drawn from the same experimental unit 
that are measured independently. While technical replicates are useful for 
assessing the variability of the assay, for most applications, biological replicates 
should be emphasized because they incorporate both the biological and the 
technical sources of variance. Furthermore, replication should occur across 
blocks that reflect principal technical sources of variance in order to avoid bias 
and to maximize generalizability. For example, an experiment should be 
performed purposefully in separate batches, even if not logistically required to do 
so, in order to obtain a more accurate effect estimate. The use of inappropriate 
replication strategies is called “pseudoreplication” and is a common problem in 
many reported studies187. An added complexity common to many OMIC 
approaches is the use of nested data, which are data featuring multiple 
observations derived from a single sample, as in the use of highly multiplexed 
signaling measurements. These nested data invalidate the presumption of 
independence. Recent reports have discussed methods to address some of 
these issues through optimal experimental design and altered strategies for 
replication188,189. 
Additional design issues include the decision of whether to pool samples, 
which is usually considered when costs must be kept low, and in sample size 
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calculation. These figures are required to estimate the number of replicates that 
the experiment must have to detect meaningful treatment effects with acceptable 
probability, if they in fact exist. Often is the case, however, that sample size is 
fixed due to logistics (e.g., cost). In such cases, strategies exist to pick optimal 
type I and type II error pairs190. 
 
Conceiving OMIC experiments: Hypotheses Or discovery? 
An additional consideration is whether the OMIC approach will be used to 
facilitate a hypothesis-driven experiment or strictly for discovery. Since the 
inception of systems biology, the validity of discovery science has been a tough 
sell to grant panels and thesis committees, who generally expect hypotheses to 
be tested191. However, specifying sensible hypotheses for OMIC experiments is 
sometimes challenging, which has led to revisiting the debate that science is only 
valid when using Popper's hypothetico-deductive logical framework191,192. In 
practice, scientific advances are made in many ways, including deduction 
(hypothesis falsification), induction (data-driven discovery)192, the question/model 
cycle191, and strong inference (propose multiple competing hypotheses and 
design experiments to discriminate them)193,194. Therefore, discovery science 
should be considered valid, at least in principle. Even so, all forms of science, 
from those that are purely discovery driven to those that are hypothesis driven, 
do need to start with a cogent and well-conceived scientific question195, and the 
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lack of a good question, not the lack of a hypothesis, likely caused the limitations 
of many studies that were based in discovery. 
 
Considerations in discovery science. 
We have observed that discovery science has pitfalls that can render 
experiments uninformative, thus wasting time, money, and effort. First, effective 
discovery experiments require just as much, if not more, careful thought in 
conception and design as do those seeking to test a hypothesis. The designs of 
these experiments are too often given insufficient thought, the reasons for which 
include a lack of training among biomedical researchers in experimental design 
and analysis178, as well as the strong temptation to just “do the experiment” 
because “we'll find something”. The latter attitude likely arises due to the desire 
to publish outcompeting the desire to seek the “truth”. 
Second, effective discovery experiments demand that the measurement 
technology measures most, if not all, of the system in an unbiased manner, such 
that the results can be reproduced and generalized. For sequencing genomes, 
this ideal is arguably met196, whereas it is almost certainly not met for the other 
OMIC methods that we discussed above, all of which are widely used in systems 
research. Therefore, the data from such experiments may be idiosyncratic to the 
specific experiment and not safely generalizable. 
Third, having a well justified hypothesis is important for determining the 
prior probability of a result being true, which in turn determines the false-positive 
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and false-negative probabilities of the result once obtained197. Accordingly, 
OMIC-based measurements based on weak or non-existent hypotheses should 
be expected to be rife with false results, which in some cases may exacerbate 
the problem of irreproducibility of biomedical science198,199. 
Given these pitfalls, it is worth highlighting that systems biology was not, 
and is not, meant to be a discovery science200. Although the term “systems 
biology” was coined at least 50 years ago, the modern era of systems biology is 
typically said to begin with the Human Genome Project201. The Human Genome 
Project and other endeavors that purely practice discovery science are 
commonly grouped with systems biology due to the use of similar OMIC 
technologies. While these fields are related, they are not the same. A relationship 
exists because discovery science aims to define the elements, whereas systems 
biology aims to define the functional relationships among these elements. 
However, in another way, discovery science and systems biology are very 
different. Discovery science and hypothesis-driven science philosophically 
contrast each other, but the same discordance does not exist between 
hypothesis-driven science and systems biology. Since its initial definition, it was 
proposed that “the integration of these two approaches, discovery and 
hypothesis-driven science, is one of the mandates of systems biology”201. Thus, 
a systems-level study is meant to use OMIC-scale data to perform predictive, 
hypothesis-driven science. Generating OMIC-scale hypotheses is challenging, 
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and systems biologists continue to struggle with casting their work in a logically 
satisfying intellectual framework. 
 
Strong hypotheses for OMIC-scale systems biology. 
The following are the three basic types of hypotheses that apply to OMIC 
experiments in signaling research: 
 
(1) The “discovery” hypothesis that at least one of the analytes will be 
affected; that is, the levels of a protein or its post-translationally modified forms 
will increase or decrease in response to at least one of the experimental 
perturbations; 
 
(2) A systems-level hypothesis pertaining to a property of the system or to 
a mathematical or computational model of the system. For example, the 
hypothesis can focus on the network topology (e.g., that it is scale free or that 
some importance can be inferred from the structure), the estimation of parameter 
values, and/or model discrimination, that is, distinguishing whether one model 
explains the data better than alternative models; and 
 
(3) Specific (reductionist) hypotheses about one or more of the measured 
analytes, for example, that c-Jun N-terminal kinase will be phosphorylated in 
response to TNF-α treatment. 
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The first type of hypothesis is the most prevalent in the systems biology 
literature, and the third type is the least prevalent. This ordering is likely due to 
the burden for finding evidence a priori to support the hypothesis. In the case of 
the first two types of hypotheses, relatively little evidence is needed for 
justification. In the case of the third type, one would have to justify distinct 
hypotheses for each analyte, which in order to do properly would require 
systematic reviewing of the relevant literature and databases for each analyte in 
order to determine how it is likely to respond to perturbations in the experiment. 
The advantage of doing this initial work prior to conducting the experiment is that 
specific elements of the design might be better resolved. Furthermore, it may 
help to alleviate the bias that could be introduced by doing the same type of 
search after the experiment to rationalize the “hits”. 
Each of these hypotheses is acceptable as long as they are exploited for 
specifying the experimental design and analysis, which is ultimately the raison 
d'être of hypotheses. In crafting a strong hypothesis, no matter the type, the 
variables must be operationalized, assumptions must be explicitly stated or 
considered, and thought must be given to the extent to which the conclusions 
can be generalized. Articulating hypotheses that contain these details facilitate 
decision making regarding the design of the experiment, the statistical analyses, 
and the appropriate interpretation of the data. In practice, bridging the gap 
between OMIC-driven discovery science and question- or hypothesis-driven 
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science often requires some form of computational or mathematical modeling. As 
with the experimental approaches discussed above, these methods each have 
distinct strengths, limitations, and design principles. 
 
Approaches to Modeling Signal Transduction Processes: 
For most signaling processes, a substantial amount of information has 
been accumulated already about the proteins involved (the parts list or “nodes”)  
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and the functional relationships or connections between these proteins (the 
“edges”). Thus, it is worth considering whether adding another node or another 
edge will improve our understanding of the system. One such example is shown 
in Fig. A.3, a wiring diagram of the integrated signaling pathways that control cell 
death, including DNA damage, cytokine, growth factor, and other stress-
response signals. The edges shown are all high confidence, meaning they  
“probably” all exist. Even so, these “probably” do not exist in all contexts, or at all 
time points, and certainly not all with the same levels of importance. The dense 
interconnectivity and temporal/contextual dependence impairs our intuitive 
understanding of how the system operates. This situation worsens with each new 
insight, whether it is new nodes or new edges. Thus, once OMIC data are 
collected for a signaling process of interest, additional tools are typically 
necessary to facilitate the transition from “data” to “understanding”. Highly 
quantitative data of the type discussed above can be modeled using various 
approaches (Fig. A.4). Different approaches might be preferred in different  
scenarios. Considerations include the nature of the data available (amount, 
specificity, level of detail, depth of information within a signaling “pathway”, 
breadth of information across parallel pathways), the size of the process being 
modeled (i.e., the number of nodes and edges), and the question being asked. 
Other more authoritative and comprehensive reviews exist for each of the 
methods that we will discuss82,202–204. Here, we survey common approaches that  
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can be used, with an emphasis on statistical approaches that may be optimal for 
studying large, complex, and imperfectly understood networks. 
 
Mechanistic and semi-mechanistic approaches 
The most commonly used framework for modeling signal transduction 
processes is kinetic modeling, which are typically expressed as ordinary 
differential equation (ODE) or partial differential equation. ODEs are attractive 
because they are a natural framework for dynamical systems such as 
signaling202. Each ODE represents the rate of change for one molecular 
component, which is a function of the rates of each biochemical transformation 
that influences the level of that component (i.e., enzyme-catalyzed reactions, 
protein–protein interactions, and transport between compartments). The rates of 
the biochemical transformations are functions of the concentrations of the 
reactants (the molecular components) and intrinsic kinetic parameters. The 
concentrations of the molecular components change over time but the kinetic 
parameter values are typically held constant. Because the molecular components 
are linked by their overlapping participation in a common set of biochemical 
reactions, the equations for the individual molecular components are organized 
into a system of interdependent ODEs. In most applications to date, the models 
were calibrated to experimental data primarily consisting of time series of protein 
levels, measured using immunoblotting, in response to experimental 
perturbations such as stimulation by receptor ligands (e.g., hormones or 
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cytokines). These models can be used to simulate the behaviors of a system 
over time and are particularly useful for testing conditions that would otherwise 
be infeasible to test (due to lack of reagents, cost, etc.). Kinetic modeling can be 
used to generate testable predictions, rule out possible mechanistic explanations 
or competing hypotheses, or identify the system parameters to which the model 
behavior is particularly sensitive or insensitive. 
The dynamic nature of signal transduction makes kinetic modeling the 
ideal framework. Indeed, some flexibility exists such that the approaches can be 
used to model spatial information205, stochastic or deterministic biological 
processes, and even responses that occur on very different timescales (e.g., cell 
division, which occurs on the timescale of hours, in response to hormone 
signaling, facets of which occur on shorter timescales). However, these 
approaches are most effective for signaling systems that are relatively well 
understood and for which the rate constants are known or can be measured 
easily. These two factors typically represent major obstacles to implementation 
because our understanding of signaling network biochemistry is far from 
complete. In particular, our understanding of crosstalk is poor for most signaling 
processes, likely due to our long history of studying signaling using reductive 
approaches. Furthermore, even for systems in which crosstalk is known to exist, 
these connections are often context specific206, thus causing an added 
complication that is only recently being explicitly explored in a systematic 
fashion207. These problems scale with the size of the modeled system, such that, 
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in practical terms, kinetic modeling is typically best suited for the study of 
relatively small signaling circuits, composed of tens of proteins, not hundreds or 
thousands. 
A reasonable compromise for many signaling systems is the use of logical 
models. These models lack the highly mechanistic insight generated from a 
kinetic model but do not require any rate parameters to be measured or 
estimated. As a result, logic models can be used generally to study much larger 
signaling networks, even in cases where connectivity is contextual or imperfectly 
understood, as is often the case in signaling biology. In a logic model, the 
signaling pathway is reconstructed as a series of logical operators—“AND,” “OR,” 
“NOR”—that describe the relationship between the activities of protein 
intermediates. This approach happens to be similar to the way signaling 
biologists have been intuitively drawing wiring diagrams since the advent of 
signal transduction as a research topic, both conceptually and with respect to 
model's output. In the simplest forms, such as those that use Boolean “on/off” 
(0,1) rules, logic models also suffer from some of the same shortcomings as 
static signal wiring diagrams. For example, the influences between proteins are 
equal in magnitude and binary, which would typically not be the case in a real 
biological system. Furthermore, these models do not traditionally provide as 
output temporal dynamics of signaling. In more sophisticated approaches, both of 
these shortcomings are addressed, and there now exist logic modeling 
frameworks that encode graded influences between pathway nodes and the time 
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dependencies of signaling activity states208,209. While these methods are still 
nascent, we predict that they will serve as important tools in the signaling 
biologist's toolkit. 
 
Data-driven modeling approaches 
Both kinetic and logic modeling methods are valuable and intuitive 
platforms; however, both methods require a reasonably mature understanding of 
the circuitry of a signaling process, the so-called “prior knowledge network”. 
Because our existing knowledge of network circuitry is incomplete, particularly in 
the area of signaling crosstalk, research in signal transduction can still benefit 
greatly from approaches that require no prior knowledge and instead are 
completely empirical and data driven. Integration of empirical insights with prior 
knowledge can often form a strong foundation to infer function or regulatory 
relationships. Data-driven approaches generally produce more abstract insights 
than mechanistic modeling but are nevertheless well suited to enhance 
understanding about the basic topology (i.e., wiring) of a signaling network, the 
influences and connectivity between network components, and the likely routes 
of information flow through a network. These approaches share the common 
underlying assumption that the relationships between signaling proteins (i.e., 
their influences and interactions) manifest as statistically observable trends within 
the data210. For example, the activities of signaling proteins that control a cellular 
response such as proliferation or apoptotic cell death would be predicted to 
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covary with these responses when measured across many diverse conditions or 
system perturbations. 
Many data-driven modeling methods exist and are becoming widely used 
in signaling research. For example, graphical network maps (protein–protein 
interaction networks, gene regulatory networks) have long been used to define 
the abstract structure of a system211. The edges that connect nodes in a graph 
can represent essentially any relationship and need not be mechanistic or 
physical in nature. Thus, networks can be a useful method for integrating 
disparate types of data212,213, as is often necessary in signaling research. When 
considered in the context of ontology or known functional groups, these networks 
can be used to make predictions about function or co-regulation. 
Clustering approaches (hierarchical, K means, K-nearest neighbors, etc.) 
are commonly used to identify subsets of the data that appear to share a 
relationship. Co-clustering might imply that the entities are themselves parts of a 
functional unit, like a multi-subunit complex, or that they are all regulated by the 
same upstream protein, or that they are all simply parts of a shared regulatory 
network. When these approaches are integrated with variables such as time and 
experimental perturbations, more mechanistic insight can be often inferred about 
why the clusters emerged and/or about the function of certain components within 
a cluster214. In this way, clustering can be a powerful hypothesis-generating tool, 
but as is true with most data-driven approaches, these hypotheses should be 
validated using other techniques, both computational and experimental215. 
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Finally, several multivariate regression and dimensionality reduction 
methods exist, including principal component analysis (PCA), partial-least-
squares regression (PLSR), stepwise regression, least absolute shrinkage and 
selection operator and elastic net regression, linear discriminant analysis, factor 
analysis, and so on. These are becoming common tools in biological research 
because of their power for describing signaling networks and their ease of use82. 
These methods take advantage of the fact that many signaling nodes carry 
redundant information or are highly covariant in response to a given stimulus. 
Dimensionality reduction approaches such as PCA can be used to simplify the 
data without losing much information. These techniques dramatically improve our 
ability to visualize complex networks and obtain a more intuitive understanding of 
how signals flow through the network. Other approaches, like PLSR, which also 
uses eigenvector decomposition, offer the ability to explicitly identify relationships 
between a set of input signals and output cellular responses. 
One important caveat in the use of data-driven modeling is the selection of 
data to be modeled. Data-driven approaches are unbiased (or at least, they are 
not biased by prior knowledge); thus, they offer an opportunity to identify novel 
and even counterintuitive or paradoxical information, provided that those signals 
were chosen to be measured. This advantage is counterbalanced by the 
limitation that spurious relationships may be identified. This limitation is not 
applicable if the data generated are truly comprehensive, but such data are rare 
in signaling research, particularly for methods that rely on antibodies as 
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described above. Thus, some thought or strategy should be applied to select 
targets for analysis that are both likely to be involved but not already known. One 
effective strategy is to combine multiple OMIC approaches, some that allow 
comprehensive analysis, to identify and prioritize certain nodes for study and 
others that allow more detailed study of signaling activation states. For example, 
global transcriptomic analysis could be used to identify processes that are 
changed in response to stimuli or activities or subnetworks that appear to be 
enriched in the transcriptional signature. Based on pathway informatics, the 
activity of some or all proteins involved in those pathways could be directly 
measured in response to stimuli over time and these data could be modeled to 
identify which signaling behaviors were most predictive of a cell fate of interest. 
This approach was used in our recent work, which studied mechanisms of drug 
synergy in triple-negative breast cancer54. Another point of caution with data-
driven modeling approaches is that variance scaling is often used to make 
comparable disparate measurements. This can lead to artifactual “stretching” of 
invariant data (i.e., data with no changes across all conditions), such that the 
model will essentially be fitting or overemphasizing experimental noise. 
There exist many excellent resources that discuss the mathematics that 
underlie each of these modeling formalisms and for describing how each can be 
used57,161,202–204,216. In the remainder of this review, we discuss considerations for 
applying these modeling methods on the types of OMIC data described and how 
their integration advances the study of signaling. 
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Considerations for modeling signaling networks. 
One overarching goal of systems biology is to build predictive models of 
cell signaling networks. Achieving this goal requires special considerations with 
respect to what to measure and when or how to measure it, in addition to the 
basic issues described above for experimental design. In general, the quality of 
existing models of cell signaling networks is deficient. These models feature 
incomplete and uncertain topologies and large uncertainties in the parameter 
values217. Importantly, these models are often still useful and, in many cases, 
have made reliable predictions that led to biological insight. 
Parameter estimation 
As we stated above, most mathematical models of signaling are kinetic 
models in which signaling is a function of the concentrations of the proteins and 
their intrinsic rates of production and decay. For most systems, the 
concentrations of most molecular components are measurable, but typically, the 
kinetic parameter values are not and must be inferred from the data using model 
optimization methods (see Sun et al.204 for a comprehensive review of 
optimization methods in systems biology). Any OMIC techniques applied for the 
purposes of calibrating or validating models of signal transduction pathways will 
have to follow the same principles. 
Two related but distinct concepts in parameter estimation are parameter 
identifiability and parameter uncertainty. The former refers to the theoretical 
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ability to learn a model parameter's true value given infinite data. Mathematically, 
an identifiable parameter will have finite confidence intervals218. Conversely, non-
identifiability implies that the true values of one or more of a model's parameters 
can never be known. Two types of parameter non-identifiability exist: structural 
and practical. Structural non-identifiability refers to redundant off-setting 
parameters in the model whereas practical non-identifiability refers to the general 
lack of data given the number of parameters219. Structural non-identifiability can 
arise in several ways such as the model having excessive parameters, 
inadequate experimental design (choice of perturbations and sampling 
strategies), or the lack of measured observables. Some of these issues can be 
resolved through model reduction techniques, but the lack of measurements can 
only be resolved by collecting qualitatively different data, either by applying 
different perturbations or by measuring additional observables. Practical non-
identifiability is alleviated by collecting data of sufficient quantity and quality. 
Specifically, these data could be qualitatively different or could be collected from 
additional or different sampling times, from additional replicates, or using more 
reliable assays with less variance. Assuming that the parameters are identifiable, 
uncertainties in their estimated values will still exist. These uncertainties are 
typically expressed as confidence intervals. Parameter uncertainties lead to 
uncertainties in the predictive power of the model, although it is possible for a 
model's predictions to be well constrained even though the parameters are 
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not220. As with the solutions to non-identifiability, parameter uncertainties can be 
reduced with data of higher quality and quantity. 
From the perspective of parameter identification, OMIC technologies will 
likely play an important role in creating better models of signal transduction. 
OMICs can help address issues of structural non-identifiability by adding 
observables. OMICs can help to constrain model topologies by identifying 
protein–protein interactions in the system of interest. The role of OMICs in 
addressing practical non-identifiability and parameter uncertainties is less clear 
because these entities are a strong function of the experimental design and the 
quality rather than quantity of the data. In this regard, one solution may be to use 
many perturbations and sampling times, which limits the applicability of certain 
OMIC techniques (such as mass spectrometry) due to the prohibitive cost of their 
use in measuring hundreds or thousands of samples. In such cases, many of the 
antibody-based “medium-throughput” proteomic techniques described above 
may represent a good compromise between the numbers of perturbations and 
observables. Accordingly, multiplexed-bead-based immunoassays, RPPAs, and 
micro-Western arrays—each of which can be applied to hundreds of samples—
have been used to supply data for computational models of signaling 
networks54,119,203,208,221. 
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Choice of perturbations, observables, and sampling times 
The power and efficiency of experimental designs for calibrating and 
validating models of cell signaling depend on the choices of what to measure and 
how to measure them, namely, the experimental perturbations (and perturbation 
sources), the observables, and the sampling times182. Of these, particularly 
important are the perturbations used to activate or deactivate signaling pathways. 
Well-chosen perturbations can reveal spurious relationships and ultimately allow 
the parameters associated with their logical and/or biochemical relationships to 
be estimated and refined. Furthermore, most topology estimation methods 
leverage the correlations between the changes in node levels in response to 
perturbation. Accurate estimation of these correlations depends on the 
sufficiency and quality of the perturbations. The combinatorial application of 
perturbations is also critical for detecting interactions (i.e., synergism or 
antagonism), which can serve as evidence for connectivity222. We believe that 
most early systems biology efforts used insufficient numbers of perturbations and 
many did not apply perturbations in a combinatorial manner. Common 
perturbations include naturally occurring variation (e.g., different cell types); 
receptor ligands such as hormones or cytokines; genetic perturbations such as 
transient, stable, or inducible overexpression or knockdown of protein; and small 
molecules, which pharmacologically activate or inhibit protein activities. The 
concentrations or doses of these variables represent experimental design 
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choices, which are often useful for contributing variation in the observables, thus 
enabling effective parameter estimation. 
Observables (i.e., what is measured) are typically the levels of total 
proteins and/or their post-translationally modified forms (e.g., phosphorylated, 
acetylated, sumoylated, etc.), as well as levels of coding and non-coding RNAs 
that are regulated by signaling pathways. Less common observables include the 
levels of protein complexes (e.g., measured by immunoprecipitation) and 
localization of proteins (e.g., protein levels in nuclear extracts). Observables are 
usually chosen on the basis of logistics, such as the availability and/or cost of 
detection reagents, but should be based more commonly on the biology (i.e., 
how is the signal encoded). Sampling times are chosen according to the 
timescale on which the signaling system operates, as well as its duration of 
action. 
 
Optimizing experimental design for modeling. 
All logistically feasible combinations of the abovementioned variables are 
possible, such that it is exceedingly difficult to choose the ones to use in a 
rational manner. In the past, these choices were made ad hoc, based on tradition 
(e.g., three replicates per treatment condition) or feasibility (e.g., availability of 
antibodies). Today, computational methods are available to optimize 
experimental designs devoted to generating data for modeling signal 
transduction networks182. Work on optimal experimental designs for signaling 
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models is still in its infancy. Early work used sensitivity analysis to prioritize 
experiments for investigating the dynamics of TNF-α/NF-κB signaling223. Casey 
et al. demonstrated the use of optimal design for constraining the variability of 
predictions in a model of EGFR signaling224, and more recently, Tidor and 
colleagues have demonstrated that optimal selection of experiments can lead to 
accurate parameter estimates in models of EGF and NGF signaling in PC12 
cells225,226. It is currently unclear as to whether computational optimization of 
experimental design is feasible for OMIC-sized models. In principle, these 
methods should be scalable but in practice may be limited by computational 
power. 
While considerable important progress has been made, these methods of 
optimization have some important limitations. First, the methods are non-trivial to 
apply. The calculations must be customized to the experimental question, which 
precludes automation and requires specialized expertise182. Second, the 
topology of the model is typically assumed to be known225, which is almost never 
the case in practice. Third, uncertainties in the input functions representing the 
perturbations must be accounted for because they can propagate into 
uncertainties in the parameter values227. These uncertainties come in many 
forms. For example, the degree to which a siRNA can knock down protein levels 
varies widely, and this information is generally unknown and not included in the 
optimization. Also, it is well established that the potencies of receptor ligands 
such as hormones and cytokines vary over time but many signaling models do 
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not incorporate this knowledge. In early models of TGF-β signaling, for example, 
the level of TGF-β was assumed to be constant228, whereas it was later found 
that TGF-β depletion is a major factor in downstream signaling kinetics229. 
Finally, experimental design optimization algorithms assume that only random 
error is present in the data despite bias being a major source of variance. Some 
biases, such as batch effects, can be eliminated by combining proper 
experimental design (blocking and randomization) with data normalization 
techniques. 
 
Data pre-processing, normalization, and statistical analysis 
All proteomic methods provide quantitative readouts that are assumed to 
be proportional to the abundance or activity of the signaling proteins of interest. 
In the case of mass spectrometry, the readout can be spectral counts or spectral 
intensities. For antibody-based proteomics, the readouts are typically 
fluorescence (e.g., the median fluorescence intensity of each bead type in a 
multiplexed-bead-based immunoassay), chemiluminescence, or optical density 
(e.g., from plate-based colorimetric assays such as ELISA). To provide 
interpretable data, these raw readouts must be translated into quantities that 
reflect the absolute or relative abundances of total or modified proteins, which 
are then further analyzed to infer the biology of the system. 
Translating raw data into interpretable quantities typically involves 
transformation, normalization, and scaling, while the downstream analyses 
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involve statistical or mathematical modeling. Log transformation is a common 
means to render the data more interpretable and to stabilize the variance of the 
signal as a function of the signal magnitude. The data are then commonly 
normalized to facilitate fair comparisons across samples or batches. 
Normalization is used to remove unwanted systematic variance from the data, 
typically that which is associated with technical sources of variance. 
Numerous normalization methods have been developed for OMIC data. 
Many of these are applicable to any type of high-throughput data, but some are 
idiosyncratic to a specific proteomic assay. Normalization methods can be 
classified into three basic types: (1) biological methods in which one or more 
separate measurements are made in order to interpret the measurement of 
interest, such as comparing the signal measure to that of an invariant 
“housekeeping” protein; (2) unsupervised methods in which models are used to 
specify putative sources of variance that are not related to the variables 
describing the study; and (3) supervised methods, which utilize study-specific 
variables including batch and treatment effects230. Different normalization 
techniques have been evaluated for mass spectrometry231, multiplexed-bead-
based flow cytometric immunoassays221, RPPAs232,233, two-dimensional gel 
electrophoresis234, antibody microarrays, immunoblotting235, and flow 
cytometry236,237. Data normalization methods continue to be developed such that 
it would be premature to declare that one approach is best, but we emphasize 
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that normalization is a critical step in the analysis of OMIC data that should be 
carefully considered. 
In addition to normalization, analysis of large signaling data sets also often 
requires scaling to compare disparate analytical measurements. The need for 
scaling is particularly critical for antibody-based proteomics because the assay 
signal intensity will be a function of both the protein expression level and 
antibody-epitope binding affinity (i.e., how “good” is the antibody), and the latter 
must be accounted for in the analysis. One common approach is to unit variance 
scale the data238, but this procedure can substantially alter the data. Specifically, 
the procedure maintains of the general “shape” of the data but disregards its 
magnitude. Situations exist in which this approach is beneficial, but for others, it 
is counterproductive. Variance rescaling can lead to misinterpretations if the 
source data were of low variance to begin with. Proper quantification, 
transformation, normalization, and scaling are all required to gain reliable insight 
using statistical or data-driven models and the “right” ways to do each of these 
depends greatly on the nature of the data collected. Another more complex issue 
is the integration of very heterogeneous types of data239. It will likely be 
necessary to integrate genomic, proteomic, or clinical data of different types, 
some of which may be categorical, continuous, or discontinuous and may have 
different sizes, formats, and parameters. Some efforts are underway to improve 
standardization and improve the ability to compare disparate data across 
different assay platforms240. This issue is complex and represents a 
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contemporary challenge for systems biology to resolve. In the meantime, efforts 
involving the integration of OMIC data sets will benefit from carefully considering 
experimental design issues and planning devoted to merging experimental and 
computational approaches in order to maximize the potential for new insights. 
 
Conclusion: 
The philosophy of OMIC experiments: Will they get us closer to the truth? 
To some, OMIC-based science represents an important way forward in 
generating comprehensive and unbiased knowledge, ultimately promising to 
reveal predictive cause-and-effect relationships about nature allowing us to 
diagnose, manage, treat, and prevent disease241. To others, the OMIC revolution 
has been a disappointment. Sydney Brenner, for example, has famously called 
systems biology a “low-input, high-throughput, no-output” science242. In light of 
these conflicting views and the roughly two decades of OMIC history on which to 
reflect, it is worth considering how far we have come and where we need to go 
moving forward. 
As we stated in the introduction, there was indeed a nascent form of 
systems biology—a version 1.0—in which the apparent idea was to do science 
as it had always been performed, but to simply do it on a larger scale: rather than 
make a knockout, make all knockouts, rank order these, and take the best one to 
study. This approach quickly morphed into a realization that these mountains of 
data could be “hypothesis generating” rather than “hypothesis driven”. It is 
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perhaps a valid criticism that this approach produced relatively few successes199. 
There are good reasons for this. For one, OMIC technologies, in and of 
themselves, did not address many of the pitfalls of biomedical science and in fact 
may have exacerbated some of these issues199. Also, early OMIC experiments 
were limited by cost feasibility, which occasionally resulted in “atypical” 
experimental designs missing some controls and/or replication. Furthermore, 
researchers had often fallen prey to the mistaken assumption that measuring 
more variables might overcome the limitations of these feasibility-limited 
experimental designs. Instead, OMIC experiments require just as much, if not 
more, care in experimental conception, design, and analysis than do traditional 
assays. As we suggested throughout this review, planning of experimental 
approaches and computational strategies should be integrated, paired with an 
understanding of the benefits and weaknesses of the approaches, and 
considered before any data are collected to ensure that the right types of data 
are collected in the right formats. An explosion of OMIC research has occurred in 
all fields of biological study, including in signal transduction. This explosion has 
been driven in part by successes in the OMIC study of genomics and 
transcriptomics. As we highlighted herein, unique challenges exist for applying 
OMIC approaches to understanding signal transduction. Importantly, however, 
common challenges exist that all OMIC researchers face in producing reliable, 
meaningful, and practical insights. We expect that many of these challenges will 
be resolved by virtue of an expanding new generation of scientists who are fluent 
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in both experimental and computational matters, and indeed, the recent additions 
to the systems literature show demonstrable progress in improving our 
understanding and treatment of human disease243. OMIC approaches or 
computational tools are not a replacement for carefully thought out questions or 
hypotheses and well-designed experiments. The idea that one should “measure 
more for the sake of measuring more” or “model more for the sake of modeling 
more” has not worked well in the past and likely will not work well in the future. In 
many (well lit) corners of biology, a frustration has been expressed with the 
relative lack of benefit brought by resource-intensive systems and OMIC 
approaches. A clear task exists for those of us in the version 2.0 of systems 
biology: prove its value. We will be judged moving forward by our ability to make 
insightful predictions, particularly ones that are either counterintuitive or could not 
have been made in the absence of OMIC or systems tools. To meet this 
mandate, we will have to be better at developing appropriate OMIC-scale 
questions or hypotheses. Each one of us must have more dexterity in the use 
and integration of various OMIC-scale experimental approaches. We will have to 
be more fluent in the proper use of computational tools. And importantly, we will 
have to be more careful in marrying these experimental and computational 
approaches appropriately. 
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